

L Number	Hits	Search Text	DB	Time stamp
84	1642	514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:08
91	534	(514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.) and (cimetidin\$ or carbonate or antiacid or antacid)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:10
98	1229	(514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.) and (cimetidin\$ or carbonate or antiacid or antacid or gastric or stomach or oral\$ or gastro\$ or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:10
112	592	(514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.) and (cimetidin\$ or carbonate or antiacid or antacid or H2 or Histamin?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:14
120	210	(514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.) and ((cimetidin\$ or carbonate or antiacid or antacid or H2 or Histamin?) with (oral? or bioavail? or gastric or gastro? or stomach or acid or acidic or acidity))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:18
127	131	((514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.) and ((cimetidin\$ or carbonate or antiacid or antacid or H2 or Histamin?) with (oral? or bioavail? or gastric or gastro? or stomach or acid or acidic or acidity))) not @ad>19981104	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:17
134	4	((514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.) and ((cimetidin\$ or carbonate or antiacid or antacid or H2 or Histamin?) with (oral? or bioavail? or gastric or gastro? or stomach or acid or acidic or acidity))) not @ad>19981104) and (pentostat\$ or cladribin\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:18
141	10	(514/42.ccls. or 514/43.ccls. or 514/45.ccls. or 514/46.ccls. or 514/47.ccls. or 514/48.ccls. or 514/52.ccls.) and ((cimetidin\$ or carbonate or antiacid or antacid or H2 or Histamin?) with (oral? or bioavail? or gastric or gastro? or stomach))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 23:19
	9	("5663155") or ("5679648") or ("5633274") or ("5310732") or ("5366960").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:35
	6	("5417986") or ("6309669") or ("6410056") or ("6447796").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:38
	22842	pentostat\$ or cladribin\$ or adenosine or adenosyl	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:04
	100741	cimetidin\$ or (calcium adj carbonate)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:43

	1407	(pentostat\$ or cladribin\$ or adenosine or adenosyl) and (cimetidin\$ or (calcium adj carbonate))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:45
	71	(pentostat\$ or cladribin\$ or adenosine or adenosyl) same (cimetidin\$ or (calcium adj carbonate))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:39
	23	(pentostat\$ or cladribin\$ or adenosine or adenosyl) with (cimetidin\$ or (calcium adj carbonate))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:46
	290	((pentostat\$ or cladribin\$ or adenosine or adenosyl) and (cimetidin\$ or (calcium adj carbonate))) and bioavail\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:43
	6	((pentostat\$ or cladribin\$ or adenosine or adenosyl) same (cimetidin\$ or (calcium adj carbonate))) and bioavail\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:42
	356851	cimetidin\$ or (carbonate)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:43
	5624	(pentostat\$ or cladribin\$ or adenosine or adenosyl) and (cimetidin\$ or (carbonate))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:45
	5584	((pentostat\$ or cladribin\$ or adenosine or adenosyl) and (cimetidin\$ or (carbonate))) and (oral\$ or gastric or gastro\$ or stomach or acid or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:55
	62	(pentostat\$ or cladribin\$ or adenosine or adenosyl) with (cimetidin\$ or (carbonate))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:46
	60	((pentostat\$ or cladribin\$ or adenosine or adenosyl) with (cimetidin\$ or (carbonate))) and (oral\$ or gastric or gastro\$ or stomach or acid or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:56
	35	((pentostat\$ or cladribin\$ or adenosine or adenosyl) with (cimetidin\$ or (carbonate))) and (oral\$ or gastric or gastro\$ or stomach or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:47
	4046	((pentostat\$ or cladribin\$ or adenosine or adenosyl) and (cimetidin\$ or (carbonate))) and (oral\$ or gastric or gastro\$ or stomach or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:55
	12386	(cimetidin\$ or (carbonate)) same (oral\$ or gastric or gastro\$ or stomach or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:59

	905	(pentostat\$ or cladribin\$ or adenosine or adenosyl) and ((cimetidin\$ or (carbonate)) same (oral\$ or gastric or gastro\$ or stomach or bioavail?))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:57
	7677	(cimetidin\$ or (calcium adj carbonate)) same (oral\$ or gastric or gastro\$ or stomach or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:58
	539	(pentostat\$ or cladribin\$ or adenosine or adenosyl) and ((cimetidin\$ or (calcium adj carbonate)) same (oral\$ or gastric or gastro\$ or stomach or bioavail?))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:59
	284	((pentostat\$ or cladribin\$ or adenosine or adenosyl) and ((cimetidin\$ or (calcium adj carbonate)) same (oral\$ or gastric or gastro\$ or stomach or bioavail?))) not @ad>19981104	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:00
	6410	(cimetidin\$ or (carbonate)) with (oral\$ or gastric or gastro\$ or stomach or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:59
	532	(pentostat\$ or cladribin\$ or adenosine or adenosyl) and ((cimetidin\$ or (carbonate)) with (oral\$ or gastric or gastro\$ or stomach or bioavail?))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:00
	4362	(cimetidin\$ or (calcium adj carbonate)) with (oral\$ or gastric or gastro\$ or stomach or bioavail?)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 16:59
	239	(pentostat\$ or cladribin\$ or adenosine or adenosyl) and ((cimetidin\$ or (calcium adj carbonate)) with (oral\$ or gastric or gastro\$ or stomach or bioavail?))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:00
	117	((pentostat\$ or cladribin\$ or adenosine or adenosyl) and ((cimetidin\$ or (calcium adj carbonate)) with (oral\$ or gastric or gastro\$ or stomach or bioavail?))) not @ad>19981104	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:18
	10	((pentostat\$ or cladribin\$ or adenosine or adenosyl) and ((cimetidin\$ or (calcium adj carbonate)) with (oral\$ or gastric or gastro\$ or stomach or bioavail?))) not @ad>19981104) and (pentostat\$ or cladribin\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:01
	186	(pentostat\$ or cladribin\$ or adenosine or adenosyl) and (antiacid or antacid)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:04
	63	(pentostat\$ or cladribin\$) and (antiacid or antacid)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:04
	82	((pentostat\$ or cladribin\$ or adenosine or adenosyl) and (antiacid or antacid)) not @ad>19981104	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/25 17:19

FILE 'CAPLUS' ENTERED AT 15:59:37 ON 25 MAR 2003

E WRENN S/IN 25

L1 5 S (E4 OR E5)

=> d 11 total ibib abs

L1 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:747650 CAPLUS
DOCUMENT NUMBER: 135:293987
TITLE: Camptothecin conjugates as proliferation inhibitors
INVENTOR(S): Wrenn, Simeon M.; Rubinfeld, Joseph
PATENT ASSIGNEE(S): Supergen, Inc., USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074402	A2	20011011	WO 2001-US6855	20010302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-540859 A1 20000331

AB A compound that includes a camptothecin conjugated to a lactone ring protecting moiety, the kits including the compound, and methods of making and using the compound for cell proliferation inhibition are described. For example, 9-nitrocampothecin (9NC) was reacted with phosgene and the resulting product was purified. The PEG phosphate diester conjugate was formed using the polyethylene glycol, averaging 100,000 mol. weight, and the 9NC phosgene product. The resulting compound was purified and used to prepare a coated stent. The stent was then deployed at the lesion site of a pig artery using a conventional stent deployment catheter and balloon. After one week, the pig was sacrificed, and the degree of restenotic growth was determined. This amount of growth was compared against a control animal where

the deployed stent was not coated.

L1 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:747649 CAPLUS
DOCUMENT NUMBER: 135:308876
TITLE: Preparation of camptothecin complexes with cyclodextrins for pharmaceuticals
INVENTOR(S): Rubinfeld, Joseph; Wrenn, Simeon M.
PATENT ASSIGNEE(S): Supergen, Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074401	A2	20011011	WO 2001-US6829	20010302
WO 2001074401	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1267936	A2	20030102	EP 2001-914662	20010302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-539982	A1 20000331
			WO 2001-US6829	W 20010302

AB Compns. include a substituted or unsubstituted camptothecin and an amorphous cyclodextrin. Methods of treating undesirable or uncontrolled cell proliferation by administering the compns. are also disclosed. Finally, implants including an implant structure and the composition are disclosed. 9-Nitrocamptothecin was treated with γ -cyclodextrin to give a complex and the complex was then tested for stability.

L1 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:314524 CAPLUS
 DOCUMENT NUMBER: 132:326077
 TITLE: Oral administration of adenosine analogs
 INVENTOR(S): Wrenn, Simeon M., Jr.
 PATENT ASSIGNEE(S): Supergen, Inc., USA
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025758	A1	20000511	WO 1999-US25676	19991101
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6174873	B1	20010116	US 1998-185909	19981104
EP 1126828	A1	20010829	EP 1999-960184	19991101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528487	T2	20020903	JP 2000-579200	19991101
PRIORITY APPLN. INFO.:			US 1998-185909	A 19981104
			WO 1999-US25676	W 19991101

AB Disclosed are compns. including an adenosine analog, wherein the composition

comprises a dosage form suitable for oral (co)administration. Also disclosed are compns. including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compns. including adenosine analogs, wherein the composition is in a dosage form comprising a liquid Pentostatin mixed with sterile water and Na saccharin was charged into a cup for oral administration.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:565916 CAPLUS
DOCUMENT NUMBER: 131:179792
TITLE: Nucleoside analogs for treatment of HIV infections
INVENTOR(S): Wrenn, Simeon M., Jr.
PATENT ASSIGNEE(S): Supergen, Inc., USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943328	A1	19990902	WO 1999-US2955	19990211
W: CA, CN, HU, IL, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2001049359	A1	20011206	US 1998-32881	19980302
CA 2320764	AA	19990902	CA 1999-2320764	19990211
EP 1056459	A1	20001206	EP 1999-906918	19990211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1998-32881	A 19980302
			WO 1999-US2955	W 19990211

AB A method of treating an HIV-infected host comprises (1) a purine or pyrimidine nucleoside that is cytotoxic or cytostatic to CD4+ T cells, but has reduced cytotoxicity to T lymphocyte stem cells and (2) a CD4+ T cell-specific antibody alone or coupled or conjugated to a moiety that is cytotoxic or cytostatic to CD4+ T cells (e.g. ricin) in combination with highly active antiretroviral therapy (HAART). A nucleoside analog is also used for ex vivo or in vitro treatment of blood derived cells, bone marrow transplants, or other organ transplants. Kits and compns. useful in the practice of the invention are also disclosed. E.g., pentostatin (4 mg/m², i.v.) was administered to an individual with AIDS who shows the presence of infective HIV once every 2 wk for 3 mo until CD+ cells, including memory cells, were at low levels. During administration of pentostatin and for a period of .apprx. 1-2 mo thereafter, or until CD+ cells recover, the patient was maintained on a maintenance dose of HAART, along with antibiotics and antifungal therapy. Stem cell or precursor cell replacement was provided through a bone marrow transplant and cytokine therapy.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:404823 CAPLUS
DOCUMENT NUMBER: 131:49486
TITLE: Local delivery of therapeutic agents

INVENTOR(S): **Wrenn, Simeon M., Jr.**
PATENT ASSIGNEE(S): **Supergen, Inc., USA**
SOURCE: **PCT Int. Appl., 54 pp.**
CODEN: **PIXXD2**
DOCUMENT TYPE: **Patent**
LANGUAGE: **English**
FAMILY ACC. NUM. COUNT: **1**
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930684	A1	19990624	WO 1998-US24151	19981112
W: AU, CA, CN, HU, IL, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2309080	AA	19990624	CA 1998-2309080	19981112
AU 9914031	A1	19990705	AU 1999-14031	19981112
EP 1037605	A1	20000927	EP 1998-957882	19981112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1997-989281	A 19971212
			WO 1998-US24151	W 19981112

AB Disclosed are implants, stents, catheters, methods and kits for the local delivery of therapeutic agents that are preferentially cytotoxic or cytostatic with regards to proliferating cells to sites where proliferative cells are present. A dispersion of 9-nitro-20(S) camptothecin was mixed with a 1% poly(L-lactic acid) solution in chloroform. This solution was then used to coat Wiktor-type stents. The coated stents were delivered in an artery at or near a tumor site, and deployed to supply 9-nitro-20(S) camptothecin to the tumor site in a localized fashion.

REFERENCE COUNT: **16** THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Page 1

=> d his

(FILE 'HOME' ENTERED AT 11:52:19 ON 25 MAR 2003)

FILE 'REGISTRY' ENTERED AT 11:52:27 ON 25 MAR 2003
E "PENTOSTATIN"/CN 25

L1 2 S E3 OR E4

FILE 'CAPLUS' ENTERED AT 11:52:50 ON 25 MAR 2003
L2 628 S L1

FILE 'REGISTRY' ENTERED AT 11:52:59 ON 25 MAR 2003
E "PENTOSTATIN"/CN 25
E "CLADRIBINE"/CN 25
L3 3 S E3 OR E4 OR E5

FILE 'CAPLUS' ENTERED AT 11:53:31 ON 25 MAR 2003
L4 599 S L3

FILE 'REGISTRY' ENTERED AT 11:53:55 ON 25 MAR 2003
E "CIMETIDINE"/CN 25
L5 9 S E3 OR E4 OR E5 OR E6 OR E7 OR E8 OR E9 OR E10 OR E11

FILE 'CAPLUS' ENTERED AT 11:54:42 ON 25 MAR 2003
L6 4553 S L5
L7 93902 L2 OR L4 OR ADENOSIN? OR ADENOSYL?
L8 260989 L6 OR CARBONATE
L9 280 L7 AND L8
L10 14 (L2 OR L4) AND L6

FILE 'STNGUIDE' ENTERED AT 12:00:09 ON 25 MAR 2003

FILE 'CAPLUS' ENTERED AT 12:09:20 ON 25 MAR 2003
L11 5 (L2 OR L4) AND CARBONATE
L12 3 L11 NOT L10

FILE 'STNGUIDE' ENTERED AT 12:10:34 ON 25 MAR 2003

FILE 'CAPLUS' ENTERED AT 12:26:31 ON 25 MAR 2003
L13 198 L9 NOT PY>1998
L14 49917 L6 OR (CALCIUM CARBONATE)
L15 54 L7 AND L14

=> d l15 total ibib abs hitstr

L15 ANSWER 1 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:38944 CAPLUS
DOCUMENT NUMBER: 138:89046
TITLE: Dietetic and pharmaceutical compositions containing
amino acids, vitamins and minerals.
PATENT ASSIGNEE(S): Kyberg Pharma Vertriebs-G.m.b.H. & Co. K.-G., Germany
SOURCE: Ger. Gebrauchsmusterschrift, 34 pp.
CODEN: GGXXFR
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 20207569	U1	20030116	DE 2002-20207569	20020514
PRIORITY APPLN. INFO.:			DE 2002-20207569	20020514
AB A composition, in particular for a supplementary balanced diet is characterized on the basis of free amino acids, one or more vitamins and one or more minerals. It contains the following amino acids (g): arginine 0.5-5, glutamine 0.5-5, lysine 0.5-5, cysteine 0.05-3, methionine 0.5-5, glycine 0.1-5, ornithine 0.5-10, tryptophan 0.1-1.5, aspartic acid 0.5-10, tyrosine 0.5-10, threonine 0.5-5, valine 0.5-10, leucine 0.5-10, isoleucine 0.5-10, proline 0.5-10, whereby the resp. quantity indicated in each case corresponds to the administered daily dose of the corresponding amino acid.				

L15 ANSWER 2 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:556104 CAPLUS
 DOCUMENT NUMBER: 137:109489
 TITLE: Compositions comprising a polypeptide and an active agent
 INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 34 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002099013	A1	20020725	US 2001-933708	20010822
PRIORITY APPLN. INFO.:			US 2000-247556P	P 20001114
			US 2000-247558P	P 20001114
			US 2000-247559P	P 20001114
			US 2000-247560P	P 20001114
			US 2000-247561P	P 20001114
			US 2000-247594P	P 20001114
			US 2000-247595P	P 20001114
			US 2000-247606P	P 20001114
			US 2000-247607P	P 20001114
			US 2000-247608P	P 20001114
			US 2000-247609P	P 20001114
			US 2000-247610P	P 20001114
			US 2000-247611P	P 20001114
			US 2000-247612P	P 20001114
			US 2000-247620P	P 20001114
			US 2000-247621P	P 20001114
			US 2000-247634P	P 20001114
			US 2000-247635P	P 20001114
			US 2000-247698P	P 20001114
			US 2000-247699P	P 20001114
			US 2000-247700P	P 20001114
			US 2000-247701P	P 20001114
			US 2000-247702P	P 20001114
			US 2000-247797P	P 20001114

US 2000-247798P P 20001114
 US 2000-247799P P 20001114
 US 2000-247800P P 20001114
 US 2000-247801P P 20001114
 US 2000-247802P P 20001114
 US 2000-247803P P 20001114
 US 2000-247804P P 20001114
 US 2000-247805P P 20001114
 US 2000-247807P P 20001114
 US 2000-247832P P 20001114
 US 2000-247833P P 20001114
 US 2000-247926P P 20001114
 US 2000-247927P P 20001114
 US 2000-247928P P 20001114
 US 2000-247929P P 20001114
 US 2000-247930P P 20001114


AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)_n-cephalexin was prepared from Glu(OBut)NCA and cephalaxin hydrochloride.

IT 51481-61-9, Cimetidine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. comprising a polypeptide and an active agent)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:429542 CAPLUS

DOCUMENT NUMBER: 137:11003

TITLE: Chondroprotective/restorative compositions containing hyaluronic acid

INVENTOR(S): Pierce, Scott W.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002068718	A1	20020606	US 2001-967977	20011002

PRIORITY APPLN. INFO.:

US 2000-237838P P 20001003

AB An oral composition based on hyaluronic acid or its salts and optionally a therapeutic drug is provided for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post-operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, and the reduction or inhibition of the production of hyaluronic acid in a mammal.

Addnl., compns. containing hyaluronic acid, chondroitin sulfate and glucosamine sulfate in a paste formulation are also described which can be administered on their own or can be used as a feed additive for cats and dogs. For example, a composition contained (by weight) glucosamine sulfate 36%, chondroitin sulfate 4%, sodium hyaluronate 0.144%, manganese sulfate 0.144%, ibuprofen 200 mg, powdered sugar 20%, glycerin 0.7%, xanthan gum 0.2%, sodium benzoate 0.7%, citric acid 0.2%, molasses 23.5%, and water 14.4%.


IT 53910-25-1, Pentostatin 70059-30-2, Cimetidine hydrochloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

RN 53910-25-1 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70059-30-2 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

L15 ANSWER 4 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:332011 CAPLUS
 DOCUMENT NUMBER: 136:355482
 TITLE: Compositions comprising a polypeptide and an active agent
 INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.
 PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034237	A1	20020502	WO 2001-US26142	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001086599	A5	20020506	AU 2001-86599	20010822
PRIORITY APPLN. INFO.:			US 2000-642820	A 20000822
			WO 2001-US26142	W 20010822

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

IT 51481-61-9, Cimetidine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. comprising a polypeptide and an active agent)


RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:330354 CAPLUS
 DOCUMENT NUMBER: 138:244
 TITLE: Binding of [³H]prazosin to α 1A- and α 1B-adrenoceptors, and to a cimetidine-sensitive non- α 1 binding site in rat kidney membranes
 AUTHOR(S): Mugisha, Paul; Gruendemann, Dirk; Schoemig, Edgar; Uhlen, Staffan
 CORPORATE SOURCE: Department of Physiology, Uppsala University, Uppsala, 751 23, Swed.
 SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (2002), 365(5), 335-340
 CODEN: NSAPCC; ISSN: 0028-1298
 PUBLISHER: Springer-Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB [3H]Prazosin bound to α 1A- and α 1B-adrenoceptors, as well as to a cimetidine-sensitive non- α 1-adrenoceptor binding site, in rat kidney membranes. An exptl. design is presented in which the α 1-adrenoceptors were selectively exposed by blocking the non- α 1 binding site with 60 μ M cimetidine. Conversely, the non- α 1 binding site could be selectively exposed by blocking the α 1-adrenoceptors with 600 nM metitepine. The identity of the non- α 1 binding site for [³H]prazosin in the rat kidney, which was pharmacol. characterized by the use of 33 competing substances, is still unknown.
 IT 51481-61-9, Cimetidine
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (prazosin binding to α 1A- and α 1B-adrenoceptors and to an unknown non- α 1 binding site in kidney membranes response to)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:185281 CAPLUS
 DOCUMENT NUMBER: 136:215525
 TITLE: Method for propagating fungi using solid state fermentation
 INVENTOR(S): Li, Pei-Jung; Shen, Chung-Guang
 PATENT ASSIGNEE(S): Globoasia LLC, USA
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020727	A2	20020314	WO 2001-US17328	20010529
WO 2002020727	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001065120	A5	20020322	AU 2001-65120	20010529
PRIORITY APPLN. INFO.: US 2000-655435 A 20000905 WO 2001-US17328 W 20010529				

AB The present invention provides a solid state fermentation (SSF) method which is effective for both small- and large-scale fungal cultivation. The present invention also provides SSF media for fungal cultivation. Although the SSF method provided in the present invention can be used in growing most fungi, the best list of fungi includes *Cordyceps sinensis*, *Ganoderma lucidum*, *Antrodia camphorata*, *Trametes versicolor*, and *Agaricus blazei*. The demonstrated SSF method not only produces high yield of fungi, but also stimulates the production of fungal metabolites, particularly the kinds with pharmaceutical and medicinal activities.

L15 ANSWER 7 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:107118 CAPLUS
 DOCUMENT NUMBER: 136:145218
 TITLE: Cancer treatment
 INVENTOR(S): Camden, James Berger; Dabek, Rose Ann
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009716	A2	20020207	WO 2001-US23427	20010725
WO 2002009716	A3	20030109		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6518269	B1	20030211	US 2000-627611	20000728


PRIORITY APPLN. INFO.:

US 2000-627611 A 20000728

OTHER SOURCE(S):

MARPAT 136:145218

GI



AB This invention is a method of treating cancer, including carcinomas and sarcomas through the administration of a pharmaceutical composition containing an


aldehyde 5-oxo-1,2,4-triazine hydrazide derivative. The aldehyde 5-oxo-1,2,4-triazine hydrazide derivative is selected from the group consisting of those with the formula (I) wherein R and R1 are independently selected from the group consisting of hydrogen, or alkyl wherein the alkyl group has ≤ 7 carbon atoms and wherein R3 is selected from the group consisting of alkyl having 1 to 7 carbon atoms, cycloalkyl having ≤ 7 carbon atoms, and substituted alkyl having ≤ 12 carbons wherein the alkyl group is substituted with one more halogen, hydroxy, amino, sulfhydryl or alkoxy having ≤ 10 carbon atoms, or substituted Ph substituted with hydrogen, alkyl of less than 7 carbons, halogen, amino, hydroxy and sulfhydryl, pharmaceutical salt, prodrug, metabolites and mixts. thereof. Pharmaceutical compns. comprising these compds. and their use in various treatment methods are claimed. The compds. can be used in conjunction with other chemotherapeutic agents and potentiators.

IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potentiator; cancer treatment using aldehyde 5-oxo-1,2,4-triazine hydrazide derivs. and other chemotherapeutic agents and potentiators)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-(2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)




RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-

pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 8 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:56490 CAPLUS

DOCUMENT NUMBER: 137:103378

TITLE: Discrimination in 5-HT₃ receptor binding in murine brain and cultured cell preparations

AUTHOR(S): Zhang, Zhang-Jin; Trivedi, Bakula L.; de Paulis, Tomas; Schmidt, Dennis E.; Hewlett, William A.

CORPORATE SOURCE: Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (2002), 365(2), 123-132

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER: Springer-Verlag


DOCUMENT TYPE: Journal

LANGUAGE: English

AB One-hundred ninety-one ligands were screened at 5-HT₃ receptors in membranes from rat brain and NCB20 cells for their ability to displace the selective, high-affinity 5-HT₃ receptor antagonist, [¹²⁵I]DAIZAC ([¹²⁵I](S)-5-chloro-3-iodo-2-methoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide). Thirty-seven compds. having structures related to benzamide, dibenzepine, serotonin, phenylbiguanide, or arylpiperazine were selected for more extensive displacement studies in membranes from rat and mouse brains, from two cultured cell preps. expressing heteromeric mouse-derived 5-HT₃ receptor proteins (NCB20 and NG108-15 cell lines), and from recombinant Sf9 cells expressing homomeric 5-HT_{3A} receptors. [¹²⁵I]DAIZAC bound specifically to a single site in each of the five tissue preps. with high affinity (KD 0.12-0.19 nM). The densities of [¹²⁵I]DAIZAC-labeled 5-HT₃ receptors were 7.4-7.5 fmol/mg protein in membranes from murine brain, and 38, 99, and 1588 fmol/mg protein in membranes from cultured NCB20, NG108-15, and recombinant Sf9 cells, resp. The affinity of substituted benzamides (n=10) was similar in all five tissue preps. The affinity of dibenzepines (n=17) was significantly higher in membranes from cultured cells as compared to membranes from rat and mouse brain, but similar in the two brain membrane preps., and in each of the cultured cell membrane preps. Serotonin-, phenylbiguanide-, and quipazine-analogs (n=10), which typically function as 5-HT (5-hydroxytryptamine) agonists, exhibited significantly higher apparent pKi values in membranes from rat brain and Sf9 recombinant cells than in membranes from the three preps. expressing heteromeric mouse-derived

5-HT₃ receptor proteins ($F=7.52$, $P<0.001$). These findings confirm that there are both species and cell-type dependent differences in binding to 5-HT₃ receptors, and that care must be taken when comparing results between exptl. paradigms that utilize different sources of 5-HT₃ receptors.

IT 51481-61-9, Cimetidine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (discrimination in 5-HT₃ receptor binding in murine brain and cultured cell preps.)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-(methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:903816 CAPLUS
 DOCUMENT NUMBER: 136:42843
 TITLE: Compositions, kits, and methods for promoting defined health benefits
 INVENTOR(S): Kern, Kenneth Norman; Heisey, Matthew Thomas
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001093847	A2	20011213	WO 2001-US17714	20010601
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1289510	A2	20030312	EP 2001-946030	20010601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:		US 2000-586213	A	20000602

US 2001-760280 A 20010112
 WO 2001-US17714 W 20010601


AB The present invention is directed to compns. comprising: (a) a first component selected from the group consisting of gelatin, cartilage, amino sugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, **S-adenosylmethionine**, salts and mixts.; and (b) a second component comprising a cation source selected from the group consisting of calcium, potassium, magnesium, and mixts. and an edible acid source. The present invention is further directed to food, beverage, pharmaceutical, over-the-counter, and dietary supplement products, which comprise the present compns. The invention also relates to kits comprising the present compns. and information that use of the composition promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention addnl. relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein. Thus, hard lemon candies are prepared by combining the following components as indicated: sugar 200, light corn syrup 63, water 60, lemon flavor glucosamine-HCl 16, and calcium citrate malate 14.9 g.

L15 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:869026 CAPLUS
 DOCUMENT NUMBER: 136:610
 TITLE: Benzimidazole carbamate compounds for cancer treatment
 INVENTOR(S): Camden, James Berger
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.
 Ser. No. 791,986.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001047021	A1	20011129	US 2001-843562	20010426
PRIORITY APPLN. INFO.:			US 2000-562709	B2 20000428
			US 2000-791986	A2 20000428

OTHER SOURCE(S): MARPAT 136:610
 GI




AB The invention is a method for treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing a

tetra-substituted benzimidazole carbamate. The tetra-substituted benzimidazole carbamates of the invention are I [X, Y, Z , A = Br, F, Cl, I, alkyl of less than 4 C, alkoxy of less than 4 C; R = H, (C1-4 alkyl)aminocarbonyl, C1-8 alkyl; R1 = aliphatic hydrocarbon of less than 7 C], or pharmaceutically acceptable salts or prodrugs thereof. Preferably R1 is an alkyl group of less than 3 C and X,Y, Z, and A are a halogen. Most preferred is 2-methoxycarbonylamino-4,5,6,7-tetrafluorobenzimidazole (preparation described). The tetra-substituted benzimidazole carbamates, and pharmaceutical compns. containing them, are claimed. X,Y,Z, and A are preferably electron-withdrawing groups.

IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazole carbamate compds. for cancer treatment)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-(methyl-N'-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thio)ethyl)- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 11 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:868198 CAPLUS

DOCUMENT NUMBER: 136:605

TITLE: Pyridinylimidazole carbamates for cancer treatment

INVENTOR(S): Camden, James Berger

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089499	A2	20011129	WO 2001-US16690	20010523
WO 2001089499	A3	20020718		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6384049	B1	20020507	US 2000-578281	20000525
US 2002019415	A1	20020214	US 2001-923126	20010806
PRIORITY APPLN. INFO.: US 2000-578281 A 20000525				
OTHER SOURCE(S): MARPAT 136:605				
GI				




AB A method is provided for treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing a pyridinylimidazole carbamate. The pyridinylimidazole carbamate is I ($X =$ halo, hydroxyl, alkyl of less than 8 C atoms, alkoxy of less than 8C atoms; $n =$ pos. integer less than 4; $R = H, C1-8$ alkyl), and pharmaceutically acceptable salts and prodrugs thereof.

IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pyridinylimidazole carbamates for cancer treatment, and use with other agents)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 12 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:816644 CAPLUS

DOCUMENT NUMBER: 135:352773

TITLE: Use of tetra-substituted benzimidazole carbamates for treating cancer

INVENTOR(S): Camden, James Berger

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083457	A2	20011108	WO 2001-US13543	20010426
WO 2001083457	A3	20020321		
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2000-562709	A 20000428
			US 2000-791986	A 20000428
OTHER SOURCE(S): GI		MARPAT 135:352773		



AB This invention is a method of treating cancer, including carcinomas and sarcomas through the administration of a pharmaceutical composition containing the title compound I [X, Y, Z, A = Br, F, Cl, I, alkyl, alkoxy; R = H, alkylaminocarbonyl, alkyl; R1 = alkyl]. Most preferred compound I is 2-methoxycarbonylamino-4,5,6,7-tetrafluorobenzimidazole which was used to treat SK-OV-3 tumor lines in nude mouse (data given). The tetra-substituted benzimidazole carbamates and pharmaceutical compns. containing them are claimed herein. X, Y, Z and A are preferably electron withdrawing groups.


IT 51481-61-9. Cimetidine 53910-25-1. 2'-Deoxycoformycin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

The (Incapacitate use),⁷ BIC (Biological Study),⁸ BCB (BCB),
(component with 2-methoxycarbonylamino-4,5,6,7-
tetrafluorobenzimidazole; use of tetra-substituted benzimidazole
carbamates for treating cancer)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)




RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-

pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 13 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:792223 CAPLUS
 DOCUMENT NUMBER: 135:348878
 TITLE: Therapeutic treatment and prevention of infections
 with a bioactive materials encapsulated within a
 biodegradable-biocompatible polymeric matrix
 INVENTOR(S): Setterstrom, Jean A.; Van Hamont, John E.; Reid,
 Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu;
 Boedeker, Edgar C.; Mcqueen, Charles E.; Jarboe,
 Daniel L.; Cassels, Frederick; Brown, William; Thies,
 Curt; Tice, Thomas R.; Roberts, F. Donald; Friden,
 Phil
 PATENT ASSIGNEE(S): United States of America as Represented by the
 Secretary of the Army, USA
 SOURCE: U.S., 141 pp., Cont.-in-part of U.S. Ser. No. 590,973,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6309669	B1	20011030	US 1997-789734	19970127
US 5417986	A	19950523	US 1992-867301	19920410
US 6410056	B1	20020625	US 1995-446148	19950522
US 6447796	B1	20020910	US 1997-920326	19970821
WO 9832427	A1	19980730	WO 1998-US1556	19980127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9863175	A1	19980818	AU 1998-63175	19980127
PRIORITY APPLN. INFO.:			US 1984-590308	B1 19840316
			US 1992-867301	A2 19920410
			US 1995-446148	A2 19950522
			US 1995-446149	B2 19950522
			US 1996-590973	B2 19960124
			US 1990-493597	B2 19900315
			US 1990-521945	B2 19900511
			US 1991-690485	B2 19910424
			US 1991-805721	B2 19911121
			US 1994-209350	B2 19940107
			US 1994-242960	A2 19940516
			US 1996-675895	A2 19960705
			US 1996-698896	A2 19960816
			US 1997-789734	A2 19970127
			WO 1998-US1556	W 19980127
AB	Novel burst-free, sustained-release biocompatible and biodegradable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiol. environment			

are disclosed. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99. Ampicillin microcapsules effectively prevented infection in 73% of rats whose wound were inoculated with ampicillin-resistant strains of *Staphilococcus aureus*, while systemic ampicillin failed in 100% of animals.


REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:687313 CAPLUS
 DOCUMENT NUMBER: 135:236410
 TITLE: Aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivatives for cancer treatment
 INVENTOR(S): Camden, James Berger
 PATENT ASSIGNEE(S): The Procter & Gamble Co., USA
 SOURCE: U.S., 11 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6290929	B1	20010918	US 2000-627610	20000728
WO 2002009715	A2	20020207	WO 2001-US23426	20010725
WO 2002009715	A3	20030103		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-627610	A 20000728
OTHER SOURCE(S):		MARPAT 135:236410		
GI				




- AB A method is provided for treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing an aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivative. The aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivative is selected from I (R, R1 = H, C1-7 alkyl), and pharmaceutical salts, prodrugs, metabolites, and mixts. thereof. Pharmaceutical compns. comprising these compds. and their use in various treatment methods are claimed. The compds. can be used in conjunction with other chemotherapeutic agents and potentiators.
- IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (potentiator; aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivs. for cancer treatment, and use with other agents)
- RN 51481-61-9 CAPLUS
- CN Guanidine, N-cyano-N'-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thio)ethyl]- (9CI) (CA INDEX NAME)



- RN 53910-25-1 CAPLUS
 CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 15 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:396644 CAPLUS
 DOCUMENT NUMBER: 135:24671
 TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
 INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
 PATENT ASSIGNEE(S): Lipocene, Inc., USA
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123
EP 1233756	A1	20020828	EP 2000-980761	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 1999-447690 A	19991123
			WO 2000-US32255 W	20001122

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of

pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT 4291-63-8, Cladribine 51481-61-9, Cimetidine


53910-25-1, Pentostatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 4291-63-8 CAPLUS


CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 16 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:338762 CAPLUS
 DOCUMENT NUMBER: 134:362292
 TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
 INVENTOR(S): Farr, Spencer
 PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
 SOURCE: PCT Int. Appl., 222 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-165398P	P 19991105
			US 2000-196571P	P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA

or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.


IT **51481-61-9**, Cimetidine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(methods of determining individual hypersensitivity to a pharmaceutical agent

from gene expression profile)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 17 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:300514 CAPLUS

DOCUMENT NUMBER: 134:331617

TITLE: Oil-in-water emulsion compositions for polyfunctional active ingredients

INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.

PATENT ASSIGNEE(S): Lipocene, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002107265	A1	20020808	US 1999-420159	19991018
PRIORITY APPLN. INFO.:			US 1999-420159	A 19991018
AB	Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and			


reduced irritation and local toxicity are described. Emulsions include an aqueous phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepared, with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captez 810D) and a long chain triglyceride (safflower oil). The composition contained (by weight) cyclosporin A 1.0, Captez 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

IT 4291-63-8, Cladribine 51481-61-9, Cimetidine
 53910-25-1, Pentostatin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oil-in-water emulsion compns. for polyfunctional active ingredients)
 RN 4291-63-8 CAPLUS
 CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS
 CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:137173 CAPLUS
 DOCUMENT NUMBER: 134:178396
 TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
 INVENTOR(S): Del Soldato, Piero
 PATENT ASSIGNEE(S): Nicox S.A., Fr.
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
WO 2001012584	A3	20020829		
			W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
BR 2000013264	A	20020416	BR 2000-13264	20000727
EP 1252133	A2	20021030	EP 2000-953102	20000727
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
NO 2002000623	A	20020409	NO 2002-623	20020208
PRIORITY APPLN. INFO.:			IT 1999-MI1817	A 19990812
			WO 2000-EP7225	W 20000727

OTHER SOURCE(S): MARPAT 134:178396
 AB Compds. or their salts of general formula (I): A-B-N(O)^s wherein: s is an integer equal to 1 or 2; A = R-T₁-, wherein R is the drug radical and T₁ = (CO)_t or (X)_{t'}, wherein X = O, S, NR₁C, R₁C is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB-X₂-O- wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X₂, bivalent radical, is such that the precursor drug of A and

the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.


IT 53910-25-1, Pentostatin

RL: RCT (Reactant); RACT (Reactant or reagent)
(antitumor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 51481-61-9, Cimetidine

RL: RCT (Reactant); RACT (Reactant or reagent)
(antiulcer; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-(methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 19 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:136991 CAPLUS

DOCUMENT NUMBER: 134:198075

TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309663	B1	20011030	US 1999-375636	19990817
EP 1210063	A1	20020605	EP 2000-947184	20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506476	T2	20030218	JP 2001-516502	20000710
US 2001024658	A1	20010927	US 2000-751968	20001229
US 6458383	B2	20021001		

PRIORITY APPLN. INFO.: US 1999-375636 A 19990817
 WO 2000-US18807 W 20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacet 186 0.20, Na taurocholate 0.18,


and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

IT 4291-63-8, Cladribine 53910-25-1, Pentostatin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RN 4291-63-8 CAPLUS

CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 20 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:742057 CAPLUS

DOCUMENT NUMBER: 133:309791

TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

INVENTOR(S): Del Soldato, Piero

PATENT ASSIGNEE(S): Nicox S.A., Fr.

SOURCE: PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
WO 2000061541	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 IT 1311923 B1 20020320 IT 1999-MI752 19990413
 BR 2000009703 A 20020108 BR 2000-9703 20000411
 EP 1169298 A2 20020109 EP 2000-926870 20000411
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002541236 T2 20021203 JP 2000-610818 20000411
 NO 2001004928 A 20011213 NO 2001-4928 20011010
 PRIORITY APPLN. INFO.: IT 1999-MI752 A 19990413
 WO 2000-EP3239 W 20000411

OTHER SOURCE(S): MARPAT 133:309791

AB Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.


IT 53910-25-1, Pentostatin

RL: RCT (Reactant); RACT (Reactant or reagent)
 (antitumor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 51481-61-9, Cimetidine

RL: RCT (Reactant); RACT (Reactant or reagent)
 (antiulcer; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:742053 CAPLUS
 DOCUMENT NUMBER: 133:310142
 TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
 INVENTOR(S): Del Soldato, Piero
 PATENT ASSIGNEE(S): Nicox S.A., Fr.
 SOURCE: PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
WO 2000061537	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1311924	B1	20020320	IT 1999-MI753	19990413
BR 2000009702	A	20020108	BR 2000-9702	20000411
EP 1169294	A2	20020109	EP 2000-925203	20000411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541233	T2	20021203	JP 2000-610814	20000411
NO 2001004927	A	20011213	NO 2001-4927	20011010
PRIORITY APPLN. INFO.:			IT 1999-MI753	A 19990413
			WO 2000-EP3234	W 20000411


OTHER SOURCE(S): MARPAT 133:310142
 AB Compds. A-B-C-N(O)s and A-C1[N(O)s]-B1 or their salts [s is an integer 1 or 2, preferably s = 2; A is the radical of a drug and is such as to meet the pharmacol. tests reported in the description; C and C1 are two bivalent radicals; the precursors of the radicals B and B1 are such as to meet the pharmacol. test reported in the description] were prepared for use as pharmaceuticals. Thus, (S,S)-N-acetyl-S-(6-methoxy- α -methyl-2-naphthalenylacetyl)cysteine 4-nitroxybutyl ester was prepared (NCX 2101) from naproxene and N-acetylcysteine in the first of 28 synthetic examples given. Pharmacol. test examples and tabular data are also given.
 IT 51481-61-9, Cimetidine 53910-25-1, Pentostatin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (drug precursor)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:553724 CAPLUS

DOCUMENT NUMBER: 133:134542

TITLE: Method for determining the microbial contamination of food packaging materials

INVENTOR(S): Buri, Matthias; Schwarzentuber, Patrick

PATENT ASSIGNEE(S): Pluss-Staufer A.-G., Switz.

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046392	A2	20000810	WO 2000-EP328	20000117
WO 2000046392	A3	20001214		
W: AT, AU, BA, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IN, JP, KR, MX, NO, NZ, PL, PT, RO, RU, SE, SI, SK, TR, US, YU RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19904057	A1	20000810	DE 1999-19904057	19990202
DE 19904057	C2	20030130		
NZ 513627	A	20010928	NZ 2000-513627	20000117
EP 1149172	A2	20011031	EP 2000-901110	20000117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 2000007965	A	20011106	BR 2000-7965	20000117

NO 2001003506	A	20011001	NO 2001-3506	20010713
PRIORITY APPLN. INFO.:			DE 1999-19904057 A	19990202
			WO 2000-EP328 W	20000117

AB The invention relates to a method for quant. and/or qual. determining the microbial contamination of suspensions, emulsions or dispersions containing minerals and/or pigments and/or fillers and/or fibrous materials, characterized in that one or more organic substances which can be decomposed by microorganisms is added to a sample of the suspensions, emulsions or dispersions, the sample is mixed, optionally incubated and then centrifuged in order to sep. the microorganisms from the minerals and/or pigments and/or fillers and/or fibrous materials. The number and/or size and/or type of microorganisms in the supernatant aqueous phase is determined after one or more incubations.

L15 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:314524 CAPLUS
 DOCUMENT NUMBER: 132:326077
 TITLE: Oral administration of **adenosine** analogs
 INVENTOR(S): Wrenn, Simeon M., Jr.
 PATENT ASSIGNEE(S): Supergen, Inc., USA
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025758	A1	20000511	WO 1999-US25676	19991101
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6174873	B1	20010116	US 1998-185909	19981104
EP 1126828	A1	20010829	EP 1999-960184	19991101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528487	T2	20020903	JP 2000-579200	19991101
PRIORITY APPLN. INFO.:			US 1998-185909 A	19981104
			WO 1999-US25676 W	19991101

AB Disclosed are compns. including an **adenosine** analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compns. including **adenosine** analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compns. including **adenosine** analogs, wherein the composition is in a dosage form comprising a liquid Pentostatin mixed with sterile water and Na saccharin was charged into a cup for oral administration.


IT 4291-63-8, Cladribine 51481-61-9, Cimetidine
 53910-25-1, Pentostatin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral administration of adenosine analogs)
RN 4291-63-8 CAPLUS
CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51481-61-9 CAPLUS
CN Guanidine, N-cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS
CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:293938 CAPLUS
DOCUMENT NUMBER: 133:129506
TITLE: Neural Network Modeling for Estimation of Partition

Coefficient Based on Atom-Type Electrotopological
State Indexes

AUTHOR(S): Huuskonen, Jarmo J.; Livingstone, David J.; Tetko, Igor V.
CORPORATE SOURCE: Division of Pharmaceutical Chemistry Department of Pharmacy, University of Helsinki, Helsinki, FIN-00014, Finland
SOURCE: Journal of Chemical Information and Computer Sciences (2000), 40(4), 947-955
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A method for predicting log P values for a diverse set of 1870 organic mols. has been developed based on atom-type electrotopol.-state (E-state) indexes and neural network modeling. An extended set of E-state indexes, which included specific indexes with a more detailed description of amino, carbonyl, and hydroxy groups, was used in the current study. For the training set of 1754 mols. the squared correlation coefficient and root-mean-squared error were $r^2 = 0.90$ and RMSLOO = 0.46, resp. Structural parameters which included mol. weight and 38 atom-type E-state indexes were used as the inputs in 39-5-1 artificial neural networks. The results from multilinear regression anal. were $r^2 = 0.87$ and RMSLOO = 0.55, resp. For a test set of 35 nucleosides, 12 nucleoside bases, 19 drug compds., and 50 general organic compds. ($n = 116$) not included in the training set, a predictive $r^2 = 0.94$ and RMS = 0.41 were calculated by artificial neural networks. The results for the same set by multilinear regression were $r^2 = 0.86$ and RMS = 0.72. The improved prediction ability of artificial neural networks can be attributed to the nonlinear properties of this method that allowed the detection of high-order relationships between E-state indexes and the n-octanol/water partition coefficient. The present approach was found to be an accurate and fast method that can be used for the reliable estimation of log P values for even the most complex structures.


IT 51481-61-9, Cimetidine

RL: PRP (Properties)

(neural network modeling for estimation of partition coefficient based on atom-type electrotopol. state indexes)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

37

THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:259972 CAPLUS

DOCUMENT NUMBER: 132:293042

TITLE: Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
 INVENTOR(S): Van Lengerich, Bernhard H.
 PATENT ASSIGNEE(S): General Mills, Inc., USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021504	A1	20000420	WO 1999-US20905	19991006
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345815	AA	20000420	CA 1999-2345815	19991006
AU 9963872	A1	20000501	AU 1999-63872	19991006
EP 1119345	A1	20010801	EP 1999-951433	19991006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527375	T2	20020827	JP 2000-575480	19991006
NO 2000004784	A	20000925	NO 2000-4784	20000925
PRIORITY APPLN. INFO.:			US 1998-103700P	P 19981009
			US 1998-109696P	P 19981124
			US 1999-233443	A 19990120
			US 1998-79060P	P 19980323
			WO 1999-US4267	W 19990323
			WO 1999-US20905	W 19991006

- AB A liquid encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liquid plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liquid plasticizer and the encapsulation of the active encapsulant is accomplished at a low temperature and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liquid content of the liquid encapsulant component provides substantially all or completely all of the liquid plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixture or dough. Removal of liquid plasticizer prior to extrusion is not needed to adjust the viscosity of the mixture for formability. Release of an active component from the matrix may be delayed or controlled over time so that the active component is delivered when and where it is needed to perform its intended function. Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant.
- IT 51481-61-9, Cimetidine

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (encapsulation of sensitive liquid components into matrix to obtain
 discrete shelf-stable particles)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:162551 CAPLUS

DOCUMENT NUMBER: 132:281870

TITLE: Adenosine 5'-triphosphate (ATP) as a proxy for bacteria numbers in deep-sea sediments and correlation with geochemical parameters (Site 994)

AUTHOR(S): Egeberg, Kristina

CORPORATE SOURCE: Agder College, Kristiansand, 4604, Norway

SOURCE: Proceedings of the Ocean Drilling Program: Scientific Results (2000), 164, 393-398

CODEN: POSRE2; ISSN: 0884-5891

PUBLISHER: Ocean Drilling Program

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sediment samples were obtained for detailed ATP (ATP) anal. down to 57.8 m below the seafloor. The samples were also analyzed for particle-size distribution, calcium carbonate (CaCO₃), organic carbon, and total nitrogen. The concns. of ATP ranged between 360 and 7050 pg g⁻¹ (dry weight sediment), which agree well with a limited number of direct bacteria

counts. Principal component analyses show that 63% of the total variance can be accounted for by the first two principal components. The concentration of

ATP (bacterial nos. by inference) is virtually independent of the concentration of sedimentary organic carbon, but correlates with CaCO₃ and coarse particles.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 27 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:403613 CAPLUS

DOCUMENT NUMBER: 131:179741

TITLE: Effects of psychoactive drugs in the Vogel conflict test in mice

AUTHOR(S): Umezawa, Toyoshi

CORPORATE SOURCE: Environmental Health Science Division, National Institute for Environmental Studies, Tsukuba, 305-0053, Japan

SOURCE: Japanese Journal of Pharmacology (1999), 80(2),
111-118

CODEN: JJPAAZ; ISSN: 0021-5198

PUBLISHER: Japanese Pharmacological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This study examined effects of various psychoactive drugs on the Vogel conflict test, where drinking behavior is punished by elec. shocks, in ICR mice to clarify the pharmacol. features of this method in mice. A benzodiazepine anxiolytic diazepam and a barbiturate pentobarbital produced significant anticonflict effects, which mean that these drugs increased the number of elec. shocks mice received during 40-min test session. On the other hand, yohimbine (α -receptor antagonist), caffeine (adenosine-receptor antagonist), scopolamine (muscarinic cholinergic antagonist), cyclazocine (σ -receptor antagonist), cimetidine (H₂-receptor antagonist), baclofen (GABAB-receptor agonist), MK-801 (NMDA-receptor antagonist), buspirone (5-HT_{1A}-receptor agonist), chlorpromazine (dopamine-receptor antagonist) and haloperidol (dopamine-receptor and σ -receptor antagonist) all did not produce anticonflict effects in this test using ICR mice. The results suggest that the Vogel conflict test is applicable to ICR mice and that this test in mice is appropriate as a screening method for drugs that have apparent anti-anxiety actions.


IT 51481-61-9, Cimetidine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of psychoactive drugs in Vogel conflict test in mice)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-(2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:246354 CAPLUS

DOCUMENT NUMBER: 129:12502

TITLE: Computer-aided video angiometry in isolated rabbit hearts: a new method assessing epicardial coronary selectivity

AUTHOR(S): Joseph, G.; Strassberger, F.; Klaus, W.

CORPORATE SOURCE: Department of Pharmacology, University of Cologne,
Cologne, D-50924, Germany

SOURCE: Journal of Pharmacological and Toxicological Methods
(1998), Volume Date 1997, 38(4), 173-179

CODEN: JPTMEZ; ISSN: 1056-8719

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal
 LANGUAGE: English


AB The clin. value of coronary vasodilators in antianginal therapy depends on the ratio of their epicardial vs. resistance coronary vessel actions. The coronary flow measured in standard isolated heart preps., however, does not allow any conclusion about the function of epicardial vessels. Thus, we established a new technique assessing the epicardial coronary diameter directly by video angiometry. Pictures from the cardiac surface were taken by a videocamera mounted on a long-distance microscope. The video signal was digitized for computer-aided evaluation. An area of interest (AOI) was laid over the vascular section to be measured. The gray values of the pixels across the epicardial vessel were registered, and a mean curve of distribution was obtained by averaging the gray values from all video lines within the AOI. The inner epicardial coronary diameter resulted from the distance between the points of inflection of this mean curve of distribution. Expts. with NO-vasodilators and **adenosine** showed that epicardial coronary arteries of isolated perfused rabbit hearts have no appreciable tone. Pretreatment of the hearts with a combination of histamine [10-6 mol/l], cimetidine [10-5 mol/l], and **adenosine** [10-7 mol/l], however, caused a marked contraction of the conductive vessels. NO-donors selectively dilated epicardial vessels in such pretreated hearts whereas **adenosine** increased both epicardial coronary diameter and coronary flow, with only a slight tendency toward preferential action on resistance vessels in low concns. Simultaneous registration of coronary flow and epicardial coronary diameter in isolated rabbit hearts pretreated with a spasmogenic drug combination (histamine, cimetidine, and **adenosine**) may be a feasible method assessing epicardial selectivity of coronary vasodilators.

IT **51481-61-9**, Cimetidine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (computer-aided video angiometry in isolated rabbit hearts: assessing epicardial coronary selectivity)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:239127 CAPLUS

DOCUMENT NUMBER: 128:312906

TITLE: Viscous hemostatic gel compositions

INVENTOR(S): Lefebvre, Jean-Marie

PATENT ASSIGNEE(S): Lefebvre, Jean-Marie, Fr.

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9815292	A1	19980416	WO 1997-FR1797	19971008
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2754183	A1	19980410	FR 1996-12415	19961008
EP 1011727	A1	20000628	EP 1997-944945	19971008
R: DE, ES, FR, IT				
PRIORITY APPLN. INFO.:			FR 1996-12415	A 19961008
			WO 1997-FR1797	W 19971008

AB The hemostatic product of the invention is active in all patients including those treated with heparin. It consists of a viscous, biol. compatible, biodegradable composition and/or capable of being biol. eliminated but which is not a collagen composition, in which is contained a hemostatic extract of snake venom, for instance batroxobin or ancrod. The viscous composition is formed in particular from hyaluronic acid, optionally esterified. An increase in the hyaluronic acid content from 1.6 to 2% increases the efficiency of the composition

IT 51481-61-9, Cimetidine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (viscous hemostatic gel compns.)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 30 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:222158 CAPLUS
 DOCUMENT NUMBER: 126:304292
 TITLE: Interaction of dipyridamole, a nucleoside transport inhibitor, with the renal transport of organic cations by LLCPK1 cells
 AUTHOR(S): Bendayan, Reina
 CORPORATE SOURCE: Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 2S2, Can.
 SOURCE: Canadian Journal of Physiology and Pharmacology (1997), 75(1), 52-56
 CODEN: CJPPA3; ISSN: 0008-4212
 PUBLISHER: National Research Council of Canada
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Dipyridamole is a well-known inhibitor of nucleoside transport by various cell membranes and is frequently used in in vitro studies that characterize nucleoside transport properties. Because interactions between the renal transport of organic cations and nucleosides have previously been suggested, the authors studied the effect of dipyridamole on the renal transport of the typical organic cations cimetidine and N1-methylnicotinamide by LLCPK1 monolayer cells grown on a permeable support. [14C]mannitol was used to correct for extracellular flux. Basolateral to apical transcellular flux (transepithelial flux-extracellular flux) of [3H]cimetidine was significantly reduced by the monolayer cells (90%) in the presence of 50 µM dipyridamole. In addition, the effect of dipyridamole on cimetidine renal transport was dose dependent ($IC_{50} = 7.7 \mu M$). The dipyridamole inhibitory effect was nearly comparable with the effect of 1 mM quinine (a typical organic cation transport inhibitor), which led to 95% inhibition of cimetidine renal transport over time. The dipyridamole effect on N1-methylnicotinamide renal transport was less potent. The effect of 1 mM of typical probes of the nucleoside transporters (i.e., thymidine, **adenosine**, uridine) and the effect of 100 mM of another nucleoside transport inhibitor, dilazep, were also studied on cimetidine transport by LLCPK1 monolayer cells. These compds. did not exert any significant effect. These results suggest that dipyridamole, a widely used nucleoside transport inhibitor, is also an inhibitor of organic cation renal transport and they alert the authors to possible interactions between the renal transport of nucleosides and organic cations. This finding also has relevance to the interpretation of in vitro studies using this agent as a nucleoside membrane transport inhibitor.

IT **51481-61-9**, Cimetidine

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (interaction of nucleoside transport inhibitor dipyridamole with renal transport of organic cations by LLCPK1 cells)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-(2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:494991 CAPLUS

DOCUMENT NUMBER: 125:159234

TITLE: Receptor regulatory properties evident in the molecular similarity of histamine and purine nucleotides


AUTHOR(S): Williams, W. R.; Pugh, W. J.; Nicholls, P. J.

CORPORATE SOURCE: Welsh Sch. Pharmacy, Cardiff Univ. Wales, Cardiff, CF1 3XF, UK

SOURCE: Pharmaceutical Sciences (1996), 2(2), 93-98

CODEN: PHSCFB; ISSN: 1356-6881

PUBLISHER: Royal Pharmaceutical Society of Great Britain
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The relative configurations of some low-mol.-weight hormones and guanosine triphosphate are similar. Because adenosine and guanosine nucleotides, in cyclic and non-cyclic forms, participate in hormone receptor activation mechanisms, this investigation of mol. similarity has been extended to both purine nucleotides and ligands operating at histamine receptor sub-types. Nitrogen atoms in mono-cation min. energy conformers of histamine and H1 agonists relate to a specific pattern of nitrogen atoms in the guanine ring. Nitrogen atoms in unchanged min. energy conformers of histamine H2 and H3 agonists relate to a different pattern of nitrogen atoms in the adenine ring. Min. energy conformers of H1, H2 and H3 antagonists fit to specific nitrogen atoms in the same purine ring system as their corresponding agonist. Structural similarity, relevant to H1 receptor activation, is also evident in histamine and arginine mols. Histamine receptor design may be based on purine nucleotide structure. Histamine H1 receptors demonstrate complementarity for the guanine ring. Histamine H2 and H3 receptors show complementarity for the adenine ring system.
 IT 51481-61-9, Cimetidine
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (receptor regulatory properties evident in the mol. similarity of histamine and purine nucleotides)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)




L15 ANSWER 32 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:713814 CAPLUS
 DOCUMENT NUMBER: 123:105279
 TITLE: Efficient peanut yield increasing agent and its preparation
 INVENTOR(S): Li, Xinghong; Peng, Lie; Li, Wei
 PATENT ASSIGNEE(S): Beijing University, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 14 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1095892	A	19941207	CN 1994-102954	19940328
CN 1056959	B	20001004		

PRIORITY APPLN. INFO.: CN 1994-102954 19940328
 AB The peanut yield increasing agent is prepared from mixed fermentation broth of Bacillus and Rhizobium, trace element, cytokinin, and absorbent. The peanut yield increasing agent is low in cost, highly efficient, and safe.

L15 ANSWER 33 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:235632 CAPLUS
 DOCUMENT NUMBER: 122:23329
 TITLE: Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth
 AUTHOR(S): Adams, W J.; Lawson, J A.; Morris, D L.
 CORPORATE SOURCE: St George Hospital, University of New South Wales, Kogarah, Australia
 SOURCE: Gut (1994), 35(11), 1632-6
 CODEN: GUTTAK; ISSN: 0017-5749
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The effect of histamine and cimetidine on the growth of four human colon cancer cell lines was studied. Histamine significantly stimulated the uptake of tritiated thymidine in vitro in a dose dependent manner, to a maximum of 120% and 116% of controls for C170 and LIM2412, resp. This effect was antagonized by cimetidine, but not diphenhydramine. Histamine also stimulated a dose dependent increase in cyclic adenosine monophosphate accumulation in C170 cells, antagonized by cimetidine. When grown as s.c. xenografts in Balb/c nu/nu mice, cimetidine had a significant inhibitory effect on the same two cell lines. The final volume of C170 tumors in animals given cimetidine was 44% of controls. This response was dose dependent, plateauing at a cimetidine dose of 50 mg/kg/day. The final volume of LIM2412 tumors in animals given cimetidine was 60% of controls. Histamine administered locally by a mini-osmotic pump stimulated C170 tumor growth to 164% of controls, was antagonized by cimetidine at a dose of 200 mg/kg/day, but not by lower concns. Histamine has a trophic effect on at least two colorectal cancer cell lines in vivo and in vitro. As this effect is antagonized by cimetidine, it may be mediated via tumor histamine type 2 receptors.
 IT 51481-61-9, Cimetidine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cimetidine inhibition of human colon cancer and reversal of histamine-stimulated in vitro and in vivo growth)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-(2-[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl)- (9CI) (CA INDEX NAME)




L15 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:191255 CAPLUS
 DOCUMENT NUMBER: 122:79868

TITLE: The acute metabolic effects of oral tricalcium phosphate and **calcium carbonate**
AUTHOR(S): Yang, R.-S.; Liu, T.-K.; Tsai, K.-S.
CORPORATE SOURCE: Dep. Lab. Medicine, College of Medicine, National Taiwan Univ., No. 7, Taipei, Taiwan
SOURCE: Calcified Tissue International (1994), 55(5), 335-41
CODEN: CTINDZ; ISSN: 0171-967X
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A double-blind study was performed to test the metabolic effects of tricalcium phosphate (TP) and **calcium carbonate** (CC) on serum calcium (SCa), serum phosphorus (SP), and immunoreactive intact serum parathyroid hormone (SPTH) levels in two groups of 24 subjects. The results showed that SCa and SP increase, whereas SPTH decreased with both preps. The increment of SCa was similar after oral load of either calcium salt in both groups. The increment of SP after TP load was more than after CC. The urinary phosphorus/creatinine ratio (UP/Cr) did not change significantly following TP, but decreased significantly after CC load in the young subjects. However, in the elderly individuals, the UP/Cr increased after TP load but did not change following CC, with statistical significance. The difference of urinary cyclic adenosine monophosphate/creatinine ratio (UcAMP/Cr) was not significant in both groups with either preparation. In summary, there was a similar rise in SCa and an equivalent fall in SPTH between TP and CC, in both young and elderly individuals.


L15 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:200269 CAPLUS
DOCUMENT NUMBER: 120:200269
TITLE: Physical compatibility of melphalan with selected drugs during simulated Y-site administration
AUTHOR(S): Trissel, Lawrence A.; Martinez, Juan F.
CORPORATE SOURCE: M. D. Anderson Cancer Cent., Univ. Texas, Houston, TX, 77030., USA
SOURCE: American Journal of Hospital Pharmacy (1993), 50(11), 2359-63
CODEN: AJHPA9; ISSN: 0002-9289
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The phys. compatibility of melphalan injection with selected drugs during simulated Y-site administration was studied. None of the drug combinations resulted in visual evidence of precipitation, color change, or gas production. Most combinations had a measured turbidity of <0.1 nephelometric turbidity unit (NTU) and were compatible. A few combinations had turbidities of ≥0.1 NTU, but the turbidity did not change over the study period and the combinations were considered compatible. Combinations of melphalan with methylprednisolone sodium succinate, prochlorperazine edisylate, or daunorubicin hydrochloride had a very small increase in turbidity but were compatible. Melphalan did not increase the doubling of turbidity that idarubicin hydrochloride shows upon simple dilution. Neither the total particle burden nor the number of particles of ≥10 µm increased in any combination that was tested. However, combinations with amphotericin B or chlorpromazine hydrochloride showed large increases in measured turbidity and were incompatible. Melphalan 0.1 mg/mL in 0.9% sodium chloride injection was phys. compatible with most of the drugs tested for up to three hours at 22°. Exceptions were

combinations with amphotericin B and with chlorpromazine hydrochloride.
 IT 53910-25-1, Pentostatin 70059-30-2, Cimetidine
 hydrochloride
 RL: BIOL (Biological study)
 (melphalan injection compatibility with, during Y-site administration)
 RN 53910-25-1 CAPLUS
 CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70059-30-2 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L15 ANSWER 36 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994:116847 CAPLUS
 DOCUMENT NUMBER: 120:116847
 TITLE: Biodegradable controlled release melt-spun delivery system
 INVENTOR(S): Fuisz, Richard C.
 PATENT ASSIGNEE(S): Fuisz Technologies, Ltd., USA
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 9324154 A1 19931209 WO 1993-US5307 19930602
 W: AU, CA, HU, JP, KR, PL, US
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 US 5518730 A 19960521 US 1992-893238 19920603
 AU 9344058 A1 19931230 AU 1993-44058 19930602
 AU 665844 B2 19960118
 JP 07507548 T2 19950824 JP 1994-500877 19930602
 EP 746342 A1 19961211 EP 1993-914373 19930602
 EP 746342 B1 20020814
 R: BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, SE
 PRIORITY APPLN. INFO.: US 1992-893238 A2 19920603
 WO 1993-US5307 A 19930602

AB Biodegradable controlled-release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dose forms as well as implants are described. For example, polyglycolide was melt-spun in combination with various drugs such as vancomycin, gentamicin, tolmetin, diphenhydramine, ibuprofen, and insulin and controlled drug release was demonstrated.


IT 53910-25-1, Pentostatin 70059-30-2, Cimetidine hydrochloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled-release pharmaceuticals formed by flash-flow melt-spinning containing, biodegradable polymers as carriers in)

RN 53910-25-1 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70059-30-2 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L15 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994:23057 CAPLUS
 DOCUMENT NUMBER: 120:23057
 TITLE: Inhibition of acetaminophen oxidation by cimetidine and the effects on glutathione and activated sulfate synthesis rates
 AUTHOR(S): Dalhoff, Kim; Poulsen, Henrik E.
 CORPORATE SOURCE: Dep. Med. A., Rigshosp., Copenhagen, DK-2100, Den.
 SOURCE: Pharmacology & Toxicology (Oxford, United Kingdom)
 (1993), 73(4), 215-18
 CODEN: PHTOEH; ISSN: 0901-9928
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The aim of the present study was to examine the effects of the hepatotoxic drug, acetaminophen, on the synthesis rates of glutathione, activated sulfate (PAPS, adenosine 3'-phosphate 5'-phosphosulfate) and the acetaminophen metabolites, acetaminophen-glutathione and acetaminophen-sulfate after inhibition of cytochrome P 450 drug oxidation by cimetidine in isolated rat hepatocytes. The synthesis rates of glutathione and PAPS were determined simultaneously by an established method based on trapping of radioactivity (³⁵S) in the prelabeled glutathione and PAPS pools. Preincubation of the hepatocytes with 60 µg/mL cimetidine for 30 min did not affect PAPS (1.71 vs. 1.78 nmol/106 cells) nor glutathione concentration (16.0 vs. 16.4 nmol/106 cells). The subsequent incubation with 5 mM acetaminophen resulted in decreased PAPS synthesis in the cimetidine treated cells. There was no difference in PAPS concentration or acetaminophen-sulfate synthesis. Decreased PAPS synthesis may be related to decreased ATP supply or may be the result of a feed-back regulation due to diversion of sulfur from glutathione synthesis to sulfoxidation. The glutathione synthesis was not significantly affected by cimetidine treatment. As expected acetaminophen-glutathione synthesis decreased by 38%. Also the glutathione concentration was lower in cimetidine treated cells. The authors have previously shown that glutathione synthesis was reduced if substrate availability decreased (acetaminophen concentration lowered). Thus, the unaltered glutathione synthesis observed in the present study in which N-acetyl-p-benzoquinoneimine formation was diminished suggests that cimetidine does not inhibit all acetaminophen metabolites which utilize reduced glutathione.
 IT 51481-61-9, Cimetidine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (acetaminophen oxidation inhibition by, hepatocyte glutathione and activated sulfate formation in relation to)

RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 38 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1993:400855 CAPLUS
 DOCUMENT NUMBER: 119:855
 TITLE: α_2 -Adrenergic, but not imidazole, agonists activate sodium chloride cotransport in rabbit tracheal epithelial cells
 AUTHOR(S): Liedtke, Carole M.; Furin, Jennifer; Ernsberger, Paul
 CORPORATE SOURCE: Cystic Fibrosis Cent., Rainbow Babies Child. Hosp., Cleveland, OH, 44106, USA
 SOURCE: American Journal of Physiology (1993), 264(3, Pt. 1), C568-C576
 CODEN: AJPHAP; ISSN: 0002-9513
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The adrenergic agonist clonidine activates NaCl cotransport in rabbit tracheocytes. With the use of the high-affinity analog p-[125I]iodoclonidine, binding of clonidine to cells was determined to fit a two-site model, with one site of high specificity for α_2 -adrenergic (α_2 -AR) and the other with a high affinity for I1-imidazol(in)e (I1) receptors. Total d. of binding sites for both receptors was similar at 18 fmol/mg protein. Moxonidine displayed a 166-fold greater specificity for I1 receptors compared with cimetidine. Bumetanide-sensitive Na or Cl transport was stimulated by the α_2 -AR agonists clonidine or guanabenz but not by the I1 agents cimetidine or moxonidine. I1 agonists-stimulated Na transport was detected only in the presence of bumetanide. Prazosin did not block clonidine-stimulated NaCl uptake or efflux, indicating the presence of an α_2 A-AR subtype. Addition of clonidine either before or after incubation with l-isoproterenol or forskolin did not attenuate the time- and dose-dependent increase in adenosine 3',5'-cyclic monophosphate (cAMP) levels. Thus clonidine stimulates NaCl cotransport in rabbit tracheocytes through an α_2 A-AR mechanism that does not require cAMP for signal transduction. In addition, I1-imidazol(in)e receptors stimulate Na transport in rabbit tracheocytes through an unidentified pathway.
 IT 51481-61-9, Cimetidine
 RL: BIOL (Biological study)
 (sodium chloride cotransport in tracheal epithelial cells response to, as imidazole agonist)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:400277 CAPLUS

DOCUMENT NUMBER: 117:277

TITLE:

Mechanism of allergic cross-reactions. I.
Multispecific binding of ligands to a mouse monoclonal anti-DNP IgE antibody

AUTHOR(S): Varga, Janos M.; Kalchschmid, Gertrud; Klein, Georg F.; Fritsch, Peter

CORPORATE SOURCE: Dep. Dermatol., Univ. Innsbruck, Innsbruck, 6020, Austria

SOURCE: Molecular Immunology (1991), 28(6), 641-54

CODEN: MOIMD5; ISSN: 0161-5890

DOCUMENT TYPE: Journal

LANGUAGE: English


AB A recently developed solid-phase binding assay was used to investigate the specificity of ligand binding to a mouse monoclonal anti-dinitrophenyl IgE (I). All DNP-amino acids, that were tested inhibited the binding of the radio-labeled I to DNP covalently attached to polystyrene microplates; however, the concentration for 50% inhibition varied within four orders of magnitude, DNP-L-serine being the most and DNP-L-proline the least potent inhibitor. In addition to DNP analogs, a large number of drugs and other compds. were tested for their ability to compete with DNP for the binding site of I. At the concentration used for screening, 59% of compds. had no significant inhibition; 19% inhibited the binding of I more than 50%. Several families of compds. (tetracyclines, polymyxins, phenothiazines, salicylates, and quinones) that were effective competitors were found. Within these families, changes in the functional groups attached to the family stem had major effects on the affinity of ligand binding. The occurrence frequencies of interactions of ligands with I is in good agreement with the semi-empirical model for multispecific antibody-ligand interactions.

IT 51481-61-9

RL: BIOL (Biological study)
(binding of, to anti-dinitrophenol monoclonal antibody, allergic cross-reaction mechanism in relation to)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RL: BIOL (Biological study)
(binding of, to anti-dinitrophenol monoclonal antibody, allergic cross-reaction mechanisms in relation to

L15 ANSWER 40 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:115047 CAPLUS
DOCUMENT NUMBER: 114:115047
TITLE: The study of Chinese herbal medicinal prescription with enzyme inhibitory activity. IV. The study of the prescription containing mineral drug with **adenosine 3',5'-cyclic monophosphate phosphodiesterase**
AUTHOR(S): Nikaido, Tamotsu; Kuge, Takashi; Kimura, Teruyo; Matsumoto, Hideko; Ohmoto, Taichi
CORPORATE SOURCE: Sch. Pharm. Sci., Toho Univ., Funabashi, 274, Japan
SOURCE: Yakugaku Zasshi (1990), 110(12), 969-73
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB Twenty-five Chinese herbal medicinal prescriptions containing gypsum, kaolin, longgu, oyster shell and Na₂SO₄ were studied for the inhibitory activity of **adenosine 3',5'-cyclic monophosphate phosphodiesterase**. The inhibitory activity of 15 prescriptions without mineral drug was higher than that of each original prescription. On the contrary, four were lower and six were not different. All 11 prescriptions containing gypsum with one exception increased the inhibitory activity by removing gypsum. The half prescriptions containing kaolin or Na₂SO₄ also increased the inhibitory activity by removing the mineral drug.

L15 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:417 CAPLUS
DOCUMENT NUMBER: 114:417
TITLE: Effects of autonomic nervous system-related agents on the intravesical pressure of the bladder in situ in female rats and aging
AUTHOR(S): Toyoshima, Atsushi; Onodera, Sadayoshi; Yoshinaga, Masaichi; Takenaga, Kunizou; Uchiyama, Toshimitsu
CORPORATE SOURCE: Sch. Med., Toho Univ., Tokyo, 143, Japan
SOURCE: Nippon Yakurigaku Zasshi (1990), 96(3), 103-15
CODEN: NYKZAU; ISSN: 0015-5691
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB The effects of several autonomic nervous system-related agents on the intravesical pressure (IVP) in adult (11- to 23-wk old) and aged (2-yr old) female rats were investigated cytometrically. Acetylcoline induced a dose-dependent and transient increase of IVP, which was competitively antagonized by pirenzepine weakly and by atropine strongly, suggesting the predominancy of M₂ receptors. Adrenaline (at only high doses), noradrenaline, and phenylephrine increased IVP but not clonidine, suggesting the predominancy of α₁ receptors. Isoproterenol, salbutamol, and clenbuterol decreased IVP to the same extent and the effect of isoproterenol was markedly antagonized by propranolol and slightly by atenolol, suggesting the predominancy of β₂ receptors. ATP increased IVP dose-dependently but not **adenosine**, suggesting the predominancy of P₂ receptors. Serotonin and prostaglandin F_{2α} also increased IVP. The maximum response to acetylcholine in aged rats was lower than in adult rats and the decrease in IVP by low doses of

adrenaline was not observed in aged rats. These results suggest that the increase of IVP involves the participation of cholinergic M₂ receptors to a large extent and also serotonergic, adrenergic α₁ and purinergic P₂ receptors to some extent and that the responsiveness to acetylcholine is reduced by aging.


IT 51481-61-9, Tagamet

RL: BIOL (Biological study)

(intravesical pressure response to acetylcholine in relation to)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:417722 CAPLUS

DOCUMENT NUMBER: 113:17722

TITLE: The effect of omeprazole on the intracellular messengers of acid secretagogues in isolated parietal cells

AUTHOR(S): Ishikawa, Tadashi; Kamisaki, Yoshinori; Itoh, Tadao

CORPORATE SOURCE: Sch. Med., Tottori Univ., Yonago, 683, Japan

SOURCE: Yonago Acta Medica (1990), 33(1), 25-36

CODEN: YOAMAQ; ISSN: 0513-5710

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of omeprazole on the second messengers of stimuli produced by acid secretagogues were examined in the parietal cells of guinea pigs. Omeprazole inhibited acid secretion stimulated by histamine, carbachol, pentagastrin and dibutyryl cyclic **adenosine monophosphate**. The manner depended on the concentration, with 50% inhibitory concentration values of

4.7-10.0 + 10⁻⁷ M, which were similar irresp. of the secretagogues. Moreover, omeprazole also inhibited the unstimulated basal acid secretion. However, incubation with omeprazole, even at a concentration of 10⁻⁴ M, did not affect the increase in cAMP which was produced by 10⁻⁷ M histamine. Similarly, it did not affect the increase in ⁴⁵Ca influx and in free cytosolic Ca²⁺ stimulated by 10⁻⁴ M carbachol. These results suggest that inhibiting the terminal step in the acid secretory process by omeprazole may not affect the concentration of the second messengers, which are produced

by the stimulation of various secretagogues.


IT 51481-61-9, Cimetidine

RL: BIOL (Biological study)

(stomach parietal cell acid secretion response to)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:16118 CAPLUS

DOCUMENT NUMBER: 112:16118

TITLE: Isolated gastric mucosa: an early approach to the study of the mechanism of action of gastric antisecretory agents

AUTHOR(S): Colombo, M.; Fort, M.; Farre, A. J.

CORPORATE SOURCE: Dep. Pharmacol., Lab. Dr. Esteve, S. A., Barcelona, 08026, Spain

SOURCE: Methods and Findings in Experimental and Clinical Pharmacology (1989), 11(10), 621-34

CODEN: MFEPDX; ISSN: 0379-0355

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The results of 5 different expts. carried out on isolated gastric mucosa were evaluated. These were: 1) effects of antisecretory agents on (H +) and (K +) in a histamine-stimulated (4 + 105M) preparation; 2) effects on (H +) in a preparation stimulated by dibutyryl cyclic adenosine monophosphate (dbcAMP) (6 + 104M); 3) reversal by antipyrine (3 + 102M) of the antacid effect of antisecretory agents in a histamine-stimulated (4 + 105M) preparation; 4) effects on the antacid activity of antisecretory agents of a pretreatment with 2-mercaptoethanol (2-ME) (2 + 102M) in a histamine-stimulated (4 + 105) preparation; and 5) reversal by intraluminal increase of (K +) (up to 144.3 mM) of the antacid effect of antisecretory agents in a histamine-stimulated (4 + 105M) preparation. The technique and its application to a series of known antisecretory agents, cimetidine, ranitidine, timoprazole and omeprazole, and to other substances with antisecretory activity such as Na thiocyanate, verapamil, trimipramine and imipramine, is described. In order to illustrate the activity of the aforementioned substances in the more classic tests of antisecretory activity, an in vivo test of inhibition of gastric secretion in pylorus-ligated rats and the in vitro tests of H₂-receptor blocking activity (isolated guinea-pig atrium), anticholinergic activity (isolated guinea-pig ileum) and carbonic anhydrase (canine blood) were included. The results show that substances with different mechanism of action behave differently in the five experiment in isolated gastric mucosa described, and these may thus be considered useful for the study of the mechanism of action of gastric antisecretory agents.

IT 51481-61-9, Cimetidine


RL: BIOL (Biological study)
(pharmacol. and mechanism of action of, as gastric antisecretory agent)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1989:89255 CAPLUS
 DOCUMENT NUMBER: 110:89255
 TITLE: Protective effects of histamine H₁ and H₂ antagonists,
adenosine and hydrocortisone on cardiac
 anaphylaxis
 AUTHOR(S): Qiu, Rong; Guo, Zhaogui
 CORPORATE SOURCE: Res. Sect. Pharmacol., Hunan Med. Univ., Changsha,
 410078, Peop. Rep. China
 SOURCE: Zhongguo Yaoli Xuebao (1989), 10(1), 34-40
 CODEN: CYLPDN; ISSN: 0253-9756
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Cardiac anaphylaxis was elicited in isolated working guinea pig hearts in
 the presence of histamine receptor antagonists (pyrilamine and
 cimetidine), **adenosine**, or hydrocortisone. Histamine
 antagonists partially inhibited the occurrence of arrhythmias during
 cardiac anaphylaxis, but did not significantly antagonize the decrease in
 cardiac function. **Adenosine** used in combination with pyrilamine
 and cimetidine manifested an apparent anti-arrhythmic effect; however, the
 attenuation of cardiac function was still present. In the presence of
 hydrocortisone plus histamine antagonists, cardiac anaphylaxis, as
 expressed by arrhythmias and a decrease in cardiac function, was
 significantly inhibited. Thus, when histamine receptor antagonists are
 used in combination with hydrocortisone, a good protective effect on
 cardiac anaphylaxis can be achieved.
 IT 51481-61-9
 RL: BIOL (Biological study)
 (cardiac anaphylaxis response to)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-
 yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 45 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1988:198173 CAPLUS
 DOCUMENT NUMBER: 108:198173
 TITLE: Effect of **adenosine**, guanidine nucleotides,
 β-adrenoagonists, and histamine H₂-receptor

antagonists on the activity of histamine-sensitive adenylylate cyclase in the gastric parietal cells of rats

AUTHOR(S): Ivashkin, V. T.; Minasyan, G. A.; Ageeva, O. G.; Konicheva, T. L.; Arutunyan, V. M.

CORPORATE SOURCE: Erevan. Gos. Med. Inst., Yerevan, USSR

SOURCE: Doklady Akademii Nauk Armyanskoi SSR (1987), 85(4), 184-8

CODEN: DANAAL; ISSN: 0366-8606

DOCUMENT TYPE: Journal


LANGUAGE: Russian

AB The effects of the title compds. on adenylylate cyclase (I) were studied in preps. from rat gastric mucosa enriched by parietal cells. The preps. were preincubated 15 min with histamine before the addition of modulators. GTP in concentration 10-5M decreased 100-times the concentration of histamine needed for half-maximum activity of I; the activation of I by GTP reached 250-300%. Adenosine in concns. 0.1-1 mM inhibited I and this effect was enhanced in the presence of GTP, although GTP alone had opposite effects. Cimetidine had a clear inhibitory effect on I. Isoproterenol stimulated I and addition of histamine further enhanced this effect, indicating additive stimulating influences mediated by H₂-receptors and β-adrenoreceptors. Hill coefficient for the interaction of I with histamine was 0.65, indicating a neg. cooperativity between the 1st and the following mols. of histamine bound to I.

IT 51481-61-9, Cimetidine
 RL: BIOL (Biological study)
 (histamine-sensitive adenylylate cyclase inhibition by, in stomach parietal cells)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1987:590828 CAPLUS
 DOCUMENT NUMBER: 107:190828
 TITLE: Reversal of opioid-induced muscular rigidity in rats:
 evidence for alpha-2 adrenergic involvement

AUTHOR(S): Jerussi, Thomas P.; Capacchione, John F.; Benvenga, Mark J.

CORPORATE SOURCE: Pharmacol. Group, Anaquest, Murray Hill, NJ, 07974,
 USA

SOURCE: Pharmacology, Biochemistry and Behavior (1987), 28(2),
 283-9

CODEN: PBBHAU; ISSN: 0091-3057

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Compds. from several different pharmacol. classes were tested for their ability to reverse the muscular rigidity induced by an i.v. dose of fentanyl that also caused loss of the righting reflex (LOR). Opioid antagonists reversed the entire syndrome (LOR and rigidity), but, generally, rigidity could be reversed nonspecifically by doses of compds. that caused LOR by themselves (e.g., central nervous system depressants). Muscle relaxants and agonists of histamine, which appeared to be acting peripherally, were also effective. On the other hand, serotonergic drugs and dopamine agonists were not. However, dopaminergic antagonists with adrenolytic activity (i.e., chlorpromazine, haloperidol) reversed rigidity, whereas sulpiride did not. Moreover, rigidity reversed by neuroleptics could be restored by piperoxane, an α_2 -adrenergic antagonist. In addition, clonidine and other α_2 -agonists selectively reversed only rigidity following systemic or central administration at doses several orders of magnitude lower than other compds. tested. Evidently opioid-induced rigidity is reversed by inhibition of sympathoadrenal outflow which can be accomplished selectively, centrally, by α_2 -agonists.

IT 51481-61-9, Cimetidine

RL: BIOL (Biological study)
(opioid-induced muscle rigidity in relation to)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thio)ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:400336 CAPLUS

DOCUMENT NUMBER: 99:336

TITLE: Different mode of action of cimetidine and prostaglandin on the rat gastric mucosa under stress loading by restraint and water-immersion

AUTHOR(S): Hasegawa, Yoshiyasu; Ohsawa, Hitoshi; Kawahara, Hiroki; Mine, Tetsuya

CORPORATE SOURCE: Fac. Med., Univ. Tokyo, Tokyo, 112, Japan


SOURCE: Gastroenterologia Japonica (1982), 17(5), 409-14

CODEN: GAJABC; ISSN: 0435-1339

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB Gastric mucosal blood flow and O₂ tension in the corporal mucosa gradually declined after water immersion in restrained control rats. Neither cimetidine (I) [51481-61-9] nor prostaglandin E2 Me ester (II) [31753-17-0] had any influence on the decrease in corporal mucosal blood flow or mucosal O₂ tension during 7 h of stress loading. Stress ulceration began to occur 3 h after cold immersion in control rats, and the deficit of energy metabolism was attributed to reduced oxidative phosphorylation from tissue hypoxia resulting from lowered blood flow and O₂ tension under stress. I (4 mg/kg)-treated animals maintained aerobic glycolysis, continued to produce high-energy phosphates, and the energy charge was unchanged in the gastric mucosa. II (100 µg/kg) showed similar, but less marked and shorter-lived effects on aerobic glycolysis and ATP production, whereas the energy charge of the adenosine pool decreased significantly from that produced by I. Apparently I significantly reduced energy requirements as compared with the control and II groups due to marked inhibition of gastric secretion and further I inhibited mucosal ulceration from water immersion stress. In addition, II reduced energy requirements through inhibition of gastric secretion. On the other hand, increased energy requirements due to increased cytoprotective mucoprotein production and a resultant decrease in energy charge were seen with II as compared with I.

IT 51481-61-9

RL: BIOL (Biological study)
(ulcer inhibition by, mechanism of, prostaglandin E2 Me ester in relation to)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-(2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 48 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1981:26665 CAPLUS

DOCUMENT NUMBER: 94:26665

TITLE: Further studies on isolated brain capillaries: some characteristics of the adenosine

triphosphatase, adenylylate- and guanylylate cyclase

AUTHOR(S): Joo, F.; Karnushina, I.; Toth, I.; Dux, E.

CORPORATE SOURCE: Biol. Res. Cent., Inst. Biophys., Szeged, Hung.

SOURCE: Circ. Dev. Aspects Brain Metab., Proc. Int. Symp. Pathophysiol. Cereb. Energy Metab., 2nd (1980), Meeting Date 1979, 181-201. Editor(s): Spatz, Maria; Mrsulja, B. B.; Rakic, Lj. M. Plenum: New York, N. Y. CODEN: 44UAAC

DOCUMENT TYPE: Conference

LANGUAGE: English


AB As observed in histochem. expts. on intact tissue and biochem. expts. on the capillary vessel fraction (isolated by d. gradient centrifugation) of the brain cortex of rats and guinea pigs, the major ATPase which is confined to the brain capillaries was Ca²⁺, Mg²⁺-ATPase. Na⁺, K⁺- and Mg²⁺-ATPases were also present in the capillary fraction, but they were present in ratios of only 1.57 and 0.97, resp., compared with the whole homogenate. Ca²⁺, Mg²⁺-ATPase in the capillaries was inhibited by dibutyryl cAMP in a dose-dependent manner. The capillary vessel fraction contained adenylate cyclase (63.2 pmol/mg/min), and this enzyme was coupled to histamine receptors, mainly of the H₂ type. The concentration of histamine required for half-maximum stimulation was .apprx.5 + 10⁻⁶M. Guanylate cyclase was also present in the capillaries, the basal activity being 20.1 pmol/mg/min. The Km for GMP was 0.25 mM. This enzyme was membrane bound and was activated by Triton X-100.

IT 51481-61-9

RL: BIOL (Biological study)
(adenylate cyclase inhibition by, kinetics of)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1980:143765 CAPLUS
DOCUMENT NUMBER: 92:143765
TITLE: The effect of adenosine triphosphate, magnesium chloride and phospholipids on crystal formation in the demineralized shell-repair membrane of the snail, *Helix pomatia* L. an in vitro study
AUTHOR(S): Abolins-Krogis, Anna
CORPORATE SOURCE: Inst. Zoophysiol., Univ. Uppsala, Uppsala, Swed.
SOURCE: Cell & Tissue Research (1979), 204(3), 497-505
CODEN: CTSRCS; ISSN: 0302-766X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effect of ATP, MgCl₂, and phospholipids on the Ca²⁺-binding activity and crystal formation within the decalcified shell-repair membrane of the snail *H. pomatia* was studied in vitro. The application of ATP produced a characteristic dual effect on calcification: (1) it strongly inhibited the formation of inorg. CaCO₃ crystals; and (2) it stimulated the development of organic crystalline bodies and induced deposition of amorphous CaCO₃. The

demineralized shell-repair membranes became white and rigid after incubation for 7 days in the medium containing 1.0 mM ATP. The inhibitory effect of Mg²⁺ on CaCO₃ crystal formation was diminished by reduction of the concentration of MgCl₂ in the incubation solution. Thus, after incubation for only

24 h, 1.0 mM MgCl₂ promoted the formation of birefringent CaCO₃ crystals within the repair membranes. The principal effect of phospholipids on the demineralized shell-repair membrane was stimulatory, but after application of phospholipids to the medium, the formation of crystals proceeded slowly. The very large, composite crystals that were formed within the repair membranes showed strong birefringence. In all cases the development of the crystals and the organic crystalline bodies occurred in close vicinity to the amebocytes.

L15 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1980:91234 CAPLUS

DOCUMENT NUMBER: 92:91234

TITLE: Ammonia forming enzymes and calcium carbonate deposition in terrestrial pulmonates

AUTHOR(S): Loest, Robert A.

CORPORATE SOURCE: Dep. Biol. Sci., Florida State Univ., Tallahassee, FL, 32306, USA

SOURCE: Physiological Zoology (1979), 52(4), 470-83
CODEN: PHZOAA; ISSN: 0031-935X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In all of 10 shelled (snails) and 4 shell-less (slugs) species, the NH₃-forming enzyme adenosine deaminase, or urease, or both were demonstrated in the mantle tissue. Adenosine deaminase predominated in 10 species and urease in only 1. NH₃ may be generated catalytically by a modified version of the purine nucleotide cycle. In all cases, the activity level of the enzyme was theor. able to account for known rates of CaCO₃ deposition. The pH optimum of either urease or adenosine deaminase from the mantle tissue of shelled species was between 8.6 and 10.0. The mantle enzyme of slugs displayed either an acidic optimum or no optimum. Tissue NH₃ levels in shelled, but not shell-less, species were ≥2.5-fold as high in the mantle as in the foot. Apparently, NH₃ is generated enzymically to enhance the rate of CaCO₃ deposition in pulmonate land snails.

L15 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1980:88330 CAPLUS

DOCUMENT NUMBER: 92:88330

TITLE: Effect of cimetidine on testosterone-induced growth and ornithine decarboxylase activity in mouse kidney

AUTHOR(S): Persson, L.; Rosengren, Elsa

CORPORATE SOURCE: Dep. Physiol. Biophys., Univ. Lund, Lund, S-223 62, Swed.

SOURCE: Journal of Physiology (Cambridge, United Kingdom) (1979), 296, 59P-60P

CODEN: JPHYA7; ISSN: 0022-3751

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In kidneys of gonadectomized mice stimulated to hypertrophy by testosterone propionate (I) [57-85-2] (200 µg s.c. 3 times daily), simultaneously administered cimetidine (II) [51481-61-9] (0-20

mg/g, in diet, daily) dose-dependently reduced ornithine decarboxylase [9024-60-6] activity. S-Adenosyl-L-methionine decarboxylase [9036-20-8] activity was unaffected by II. Kidney weight was reduced in mice given I and II for 3 days from 355 to 322 and 311 by 10.0 and 2.0 mg II/g, resp. Thus, II interferes with polyamine formation in the I-stimulated hypertrophic mouse kidney.


IT 51481-61-9

RL: BIOL (Biological study)

(ornithine decarboxylase inhibition by, in testosterone-stimulated kidney)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1970:50892 CAPLUS

DOCUMENT NUMBER: 72:50892

TITLE: Ammonia and biological deposition of calcium carbonate

AUTHOR(S): Campbell, James Wayne; Speeg, K. V., Jr.

CORPORATE SOURCE: Rice Univ., Houston, TX, USA

SOURCE: Nature (London, United Kingdom) (1969), 224(5220), 725-6

CODEN: NATUAS; ISSN: 0028-0836

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effect of NH₃ in the deposition of CaCO₃ in biol. systems which deposit this salt (e.g., snails), as well as the known involvement of carbonic anhydrase in the biol. formation of CaCO₃ may be summarized in the equation: NH₃ + HCO₃⁻ + Ca²⁺ = CaCO₃ + NH₄⁺, and has also been considered as a model for the geochem. deposition of CaCO₃ in certain circumstance s. NH₃ reportedly arises in snails from (NH₄)₂CO by the action of their tissue urease, and there is evidence that snails synthesize (NH₄)₂CO for this purpose. The (NH₄)₂CO carbon (as well as that of the guanidino group of arginine) is also a precursor of shell CO₃²⁻, but its incorporation appears to take place via HCO₃⁻. Preliminary observations have also indicated that NH₃ may play a part in the avian (White Leghorn hen) eggshell-forming system, with NH₄⁺ ac cumulating around the calcifying egg in the shell gland. The absence of urease in vertebrates led to the selection of adenosine deaminase (I) as the source of NH₃ in the avian reproductive tract; the high levels of I reported in the lung tissues of some mammals have also led to the suggestion that I acts in these tissues in an NH₃-forming capacity. According to the Diamantstein (1966) model, the metabolic acidosis reported in the laying hen would be caused partly by NH₄⁺ passing back into the blood through the shell gland.

L15 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1965:2126 CAPLUS
DOCUMENT NUMBER: 62:2126
ORIGINAL REFERENCE NO.: 62:333e-g
TITLE: The inhibitory effects of some metabolites on the precipitation of CaCO₃ from artificial and natural sea water
AUTHOR(S): Simkiss, K.
CORPORATE SOURCE: Duke Univ., Durham, NC
SOURCE: J. Conseil, Conseil Perm. Intern. Exploration Mer (1964), 29(1), 6-18
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Sea water is highly supersatd. with respect to calcite and frequently slightly supersatd. with respect to aragonite. Expts. indicate that perhaps the precipitation of CaCO₃ is being inhibited by some substance in natural sea water. The addition of Na **adenosine** triphosphate, Na glycerophosphate, or Na₄P₂O₇ in dilns. down to 10-6M produced the same inhibiting effects in artificial sea water. Passing natural sea water through an anion exchange column removed much of the inhibitory substance. Incubation of the sea water with alkaline phosphatase and other attempts at destroying the inhibitor by hydrolysis did not produce any effect on the ability to precipitate CaCO₃. The addition of orthophosphate to artificial sea water reproduced the effects found in natural sea water and this inhibition started to break down at a concentration of .apprx.10-6M. Borates and silicates had no effect upon the precipitation of CaCO₃ from the artificial sea water. Natural sea water contains some phosphate compds. that act as crystals poisons to the formation of precipitates of CaCO₃.

L15 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1962:425482 CAPLUS
DOCUMENT NUMBER: 57:25482
ORIGINAL REFERENCE NO.: 57:5133i,5134a-c
TITLE: Phosphorus content of Eristalomyia tenax
AUTHOR(S): Jarczyk, H. J.
SOURCE: Z. Vergleich. Physiol. (1957), 40, 363-75
From: Biol. Abstr. 36, Abstr. No. 34454 (1961).
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB The presence of P was investigated in pressed egg juice, larval hemolymph, eggs, larvae, pupae, and imagos during metamorphosis. A relation exists between the outside temperature and the acid-soluble inorg. and readily hydrolyzable phosphate. The acid-soluble inorg. phosphate of the larval hemolymph is dependent upon the P content of the medium surrounding the larva. The acid-soluble inorg. and readily hydrolyzable P compds. of the larval hemolymph decrease with an increase in the age of the larva with a simultaneous increase in the total acid-soluble compds. The acid-soluble organic P compds. of the eggs and larval hemolymph are esters. The larval hemolymph contains an enzyme capable of hydrolyzing **adenosine** triphosphate. The total P content decreases with increasing age of the animal except for the pupa. It increases slightly with imagos. The water content of the eggs runs parallel with their total P content. It decreases from the young larva to the pupa and again increases slightly with the imagos until the time of hatching. The total P content of the

male is higher at the time of hatching than that of the female. The same total P content was found in the 3 stages of the larva after a week of hunger. The hemolymph of young larvae contains very little protein which can be precipitated with CCl₃COOH in contrast to the hemolymph of mature larvae.

Hemolymph of young larvae only becomes slightly black in the presence of air, while pupal hemolymph immediately darkens. This shows the great reconstruction of protein. The pupal exuvia consist of more than 50% CaCO₃.

Page 1

=> d his

(FILE 'HOME' ENTERED AT 11:52:19 ON 25 MAR 2003)

FILE 'REGISTRY' ENTERED AT 11:52:27 ON 25 MAR 2003
E "PENTOSTATIN"/CN 25

L1 2 S E3 OR E4

FILE 'CAPLUS' ENTERED AT 11:52:50 ON 25 MAR 2003
L2 628 S L1

FILE 'REGISTRY' ENTERED AT 11:52:59 ON 25 MAR 2003
E "PENTOSTATIN"/CN 25
E "CLADRIBINE"/CN 25
L3 3 S E3 OR E4 OR E5

FILE 'CAPLUS' ENTERED AT 11:53:31 ON 25 MAR 2003
L4 599 S L3

FILE 'REGISTRY' ENTERED AT 11:53:55 ON 25 MAR 2003
E "CIMETIDINE"/CN 25
L5 9 S E3 OR E4 OR E5 OR E6 OR E7 OR E8 OR E9 OR E10 OR E11

FILE 'CAPLUS' ENTERED AT 11:54:42 ON 25 MAR 2003
L6 4553 S L5

=> 12 or 14 or adenosin? or adenosyl?

84349 ADENOSIN?

10072 ADENOSYL?

L7 93902 L2 OR L4 OR ADENOSIN? OR ADENOSYL?

=> 16 or carbonate

227050 CARBONATE

57939 CARBONATES

256523 CARBONATE

(CARBONATE OR CARBONATES)

L8 260989 L6 OR CARBONATE

=> 17 and 18

L9 280 L7 AND L8

=> (12 or 14) and 16

L10 14 (L2 OR L4) AND L6

=> d his

(FILE 'HOME' ENTERED AT 11:52:19 ON 25 MAR 2003)

FILE 'REGISTRY' ENTERED AT 11:52:27 ON 25 MAR 2003
E "PENTOSTATIN"/CN 25

L1 2 S E3 OR E4

FILE 'CAPLUS' ENTERED AT 11:52:50 ON 25 MAR 2003
L2 628 S L1

FILE 'REGISTRY' ENTERED AT 11:52:59 ON 25 MAR 2003
E "PENTOSTATIN"/CN 25

L3 E "CLADRIBINE"/CN 25
3 S E3 OR E4 OR E5

L4 FILE 'CAPLUS' ENTERED AT 11:53:31 ON 25 MAR 2003
599 S L3

L5 FILE 'REGISTRY' ENTERED AT 11:53:55 ON 25 MAR 2003
E "CIMETIDINE"/CN 25
9 S E3 OR E4 OR E5 OR E6 OR E7 OR E8 OR E9 OR E10 OR E11

L6 FILE 'CAPLUS' ENTERED AT 11:54:42 ON 25 MAR 2003
4553 S L5

L7 93902 L2 OR L4 OR ADENOSIN? OR ADENOSYL?

L8 260989 L6 OR CARBONATE

L9 280 L7 AND L8

L10 14 (L2 OR L4) AND L6

=> d l10 total ibib abs hitstr

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:429542 CAPLUS
DOCUMENT NUMBER: 137:11003
TITLE: Chondroprotective/restorative compositions containing hyaluronic acid
INVENTOR(S): Pierce, Scott W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002068718	A1	20020606	US 2001-967977	20011002
PRIORITY APPLN. INFO.:			US 2000-237838P	P 20001003

AB An oral composition based on hyaluronic acid or its salts and optionally a therapeutic drug is provided for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post-operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, and the reduction or inhibition of the production of hyaluronic acid in a mammal.

Addnl., compns. containing hyaluronic acid, chondroitin sulfate and glucosamine sulfate in a paste formulation are also described which can be administered on their own or can be used as a feed additive for cats and dogs. For example, a composition contained (by weight) glucosamine sulfate 36%, chondroitin sulfate 4%, sodium hyaluronate 0.144%, manganese sulfate 0.144%, ibuprofen 200 mg, powdered sugar 20%, glycerin 0.7%, xanthan gum 0.2%, sodium benzoate 0.7%, citric acid 0.2%, molasses 23.5%, and water 14.4%.


IT 53910-25-1, Pentostatin 70059-30-2, Cimetidine hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

RN 53910-25-1 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70059-30-2 CAPLUS

CN Guanidine, N-cyano-N'-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thio)ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:107118 CAPLUS

DOCUMENT NUMBER: 136:145218

TITLE: Cancer treatment

INVENTOR(S): Camden, James Berger; Dabek, Rose Ann

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009716	A2	20020207	WO 2001-US23427	20010725
WO 2002009716	A3	20030109		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,


CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6518269 B1 20030211 US 2000-627611 20000728

PRIORITY APPLN. INFO.: US 2000-627611 A 20000728

OTHER SOURCE(S): MARPAT 136:145218

GI



AB This invention is a method of treating cancer, including carcinomas and sarcomas through the administration of a pharmaceutical composition containing an aldehyde 5-oxo-1,2,4-triazine hydrazide derivative. The aldehyde 5-oxo-1,2,4-triazine hydrazide derivative is selected from the group consisting of those with the formula (I) wherein R and R1 are independently selected from the group consisting of hydrogen, or alkyl wherein the alkyl group has ≤ 7 carbon atoms and wherein R3 is selected from the group consisting of alkyl having 1 to 7 carbon atoms, cycloalkyl having ≤ 7 carbon atoms, and substituted alkyl having ≤ 12 carbons wherein the alkyl group is substituted with one more halogen, hydroxy, amino, sulfhydryl or alkoxy having ≤ 10 carbon atoms, or substituted Ph substituted with hydrogen, alkyl of less than 7 carbons, halogen, amino, hydroxy and sulfhydryl, pharmaceutical salt, prodrug, metabolites and mixts. thereof. Pharmaceutical compns. comprising these compds. and their use in various treatment methods are claimed. The compds. can be used in conjunction with other chemotherapeutic agents and potentiators.


IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(potentiator; cancer treatment using aldehyde 5-oxo-1,2,4-triazine hydrazide derivs. and other chemotherapeutic agents and potentiators)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:869026 CAPLUS

DOCUMENT NUMBER: 136:610

TITLE: Benzimidazole carbamate compounds for cancer treatment

INVENTOR(S): Camden, James Berger

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 791,986.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001047021	A1	20011129	US 2001-843562	20010426
PRIORITY APPLN. INFO.:			US 2000-562709	B2 20000428
			US 2000-791986	A2 20000428
OTHER SOURCE(S):	MARPAT	136:610		
GI				




AB The invention is a method for treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing a

tetra-substituted benzimidazole carbamate. The tetra-substituted benzimidazole carbamates of the invention are I [X, Y, Z , A = Br, F, Cl, I, alkyl of less than 4 C, alkoxy of less than 4 C; R = H, (C1-4 alkyl)aminocarbonyl, C1-8 alkyl; R1 = aliphatic hydrocarbon of less than 7 C], or pharmaceutically acceptable salts or prodrugs thereof. Preferably R1 is an alkyl group of less than 3 C and X,Y, Z, and A are a halogen. Most preferred is 2-methoxycarbonylamino-4,5,6,7-tetrafluorobenzimidazole (preparation described). The tetra-substituted benzimidazole carbamates, and pharmaceutical compns. containing them, are claimed. X,Y,Z, and A are preferably electron-withdrawing groups.

IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazole carbamate compds. for cancer treatment)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-(2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:868198 CAPLUS
 DOCUMENT NUMBER: 136:605
 TITLE: Pyridinylimidazole carbamates for cancer treatment
 INVENTOR(S): Camden, James Berger
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089499	A2	20011129	WO 2001-US16690	20010523
WO 2001089499	A3	20020718		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6384049	B1	20020507	US 2000-578281	20000525
US 2002019415	A1	20020214	US 2001-923126	20010806
PRIORITY APPLN. INFO.:			US 2000-578281	A 20000525
OTHER SOURCE(S):		MARPAT 136:605		
GI				




AB A method is provided for treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing a pyridinylimidazole carbamate. The pyridinylimidazole carbamate is I ($X =$ halo, hydroxyl, alkyl of less than 8 C atoms, alkoxy of less than 8C atoms; $n =$ pos. integer less than 4; R = H, C1-8 alkyl), and pharmaceutically acceptable salts and prodrugs thereof.

IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyridinylimidazole carbamates for cancer treatment, and use with other agents)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:816644 CAPLUS

DOCUMENT NUMBER: 135:352773

TITLE: Use of tetra-substituted benzimidazole carbamates for treating cancer

INVENTOR(S): Camden, James Berger

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083457	A2	20011108	WO 2001-US13543	20010426
WO 2001083457	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-562709	A 20000428
			US 2000-791986	A 20000428
OTHER SOURCE(S):		MARPAT 135:352773		
GI				



AB This invention is a method of treating cancer, including carcinomas and sarcomas through the administration of a pharmaceutical composition containing the


title compound I [X, Y, Z, A = Br, F, Cl, I, alkyl, alkoxy; R = H, alkylaminocarbonyl, alkyl; R1 = alkyl]. Most preferred compound I is 2-methoxycarbonylamino-4,5,6,7-tetrafluorobenzimidazole which was used to treat SK-OV-3 tumor lines in nude mouse (data given). The tetra-substituted benzimidazole carbamates and pharmaceutical compns. containing them are claimed herein. X, Y, Z and A are preferably electron withdrawing groups.

IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(component with 2-methoxycarbonylamino-4,5,6,7-
tetrafluorobenzimidazole; use of tetra-substituted benzimidazole
carbamates for treating cancer)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:687313 CAPLUS

DOCUMENT NUMBER: 135:236410

TITLE: Aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivatives for cancer treatment

INVENTOR(S): Camden, James Berger

PATENT ASSIGNEE(S): The Procter & Gamble Co., USA

SOURCE: U.S., 11 pp.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6290929	B1	20010918	US 2000-627610	20000728
WO 2002009715	A2	20020207	WO 2001-US23426	20010725
WO 2002009715	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2000-627610 A 20000728				
OTHER SOURCE(S): MARPAT 135:236410				
GI				




- AB A method is provided for treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing an aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivative. The aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivative is selected from I (R, R1 = H, C1-7 alkyl), and pharmaceutical salts, prodrugs, metabolites, and mixts. thereof. Pharmaceutical compns. comprising these compds. and their use in various treatment methods are claimed. The compds. can be used in conjunction with other chemotherapeutic agents and potentiators.
- IT 51481-61-9, Cimetidine 53910-25-1, 2'-Deoxycoformycin
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (potentiator; aryl aldehyde 5-oxo-1,2,4-triazine hydrazide derivs. for cancer treatment, and use with other agents)
- RN 51481-61-9 CAPLUS
- CN Guanidine, N-cyano-N'-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thio)ethyl]- (9CI) (CA INDEX NAME)



- RN 53910-25-1 CAPLUS
 CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:396644 CAPLUS

DOCUMENT NUMBER: 135:24671

TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing

PATENT ASSIGNEE(S): Lipocene, Inc., USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123
EP 1233756	A1	20020828	EP 2000-980761	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 1999-447690	A 19991123
			WO 2000-US32255	W 20001122

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of

pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT 4291-63-8, Cladribine 51481-61-9, Cimetidine


53910-25-1, Pentostatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 4291-63-8 CAPLUS


CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:300514 CAPLUS

DOCUMENT NUMBER: 134:331617

TITLE: Oil-in-water emulsion compositions for polyfunctional active ingredients

INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.

PATENT ASSIGNEE(S): Lipocene, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002107265	A1	20020808	US 1999-420159	19991018

PRIORITY APPLN. INFO.: US 1999-420159 A 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aqueous phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepared, with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The composition

contained (by weight) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

IT 4291-63-8, Cladribine 51481-61-9, Cimetidine


53910-25-1, Pentostatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oil-in-water emulsion compns. for polyfunctional active ingredients)

RN 4291-63-8 CAPLUS


CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS


RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:137173 CAPLUS
 DOCUMENT NUMBER: 134:178396
 TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
 INVENTOR(S): Del Soldato, Piero
 PATENT ASSIGNEE(S): Nicox S.A., Fr.
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
WO 2001012584	A3	20020829		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013264	A	20020416	BR 2000-13264	20000727
EP 1252133	A2	20021030	EP 2000-953102	20000727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2002000623	A	20020409	NO 2002-623	20020208
PRIORITY APPLN. INFO.:			IT 1999-MI1817	A 19990812
			WO 2000-EP7225	W 20000727

OTHER SOURCE(S): MARPAT 134:178396
 AB Compds. or their salts of general formula (I): A-B-N(O)s wherein: s is an integer equal to 1 or 2; A = R-T1-, wherein R is the drug radical and T1 = (CO)_t or (X)_{t'}, wherein X = O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB-X2-O- wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X2, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.
 IT 53910-25-1, Pentostatin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (antitumor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
 RN 53910-25-1 CAPLUS
 CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 51481-61-9, Cimetidine

RL: RCT (Reactant); RACT (Reactant or reagent)
 (antiulcer; synthesis, activity and formulations of pharmaceutical
 compds. for treatment of oxidative stress and/or endothelial
 dysfunction)

RN 51481-61-9 CAPLUS

CN Guanidine, N-cyano-N'-(2-[(5-methyl-1H-imidazol-4-yl)methyl]thioethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:742057 CAPLUS

DOCUMENT NUMBER: 133:309791

TITLE: Synthesis, activity and formulations of pharmaceutical
 compounds for treatment of oxidative stress and/or
 endothelial dysfunction

INVENTOR(S): Del Soldato, Piero

PATENT ASSIGNEE(S): Nicox S.A., Fr.

SOURCE: PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
WO 2000061541	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 IT 1311923 B1 20020320 IT 1999-MI752 19990413
 BR 2000009703 A 20020108 BR 2000-9703 20000411
 EP 1169298 A2 20020109 EP 2000-926870 20000411
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002541236 T2 20021203 JP 2000-610818 20000411
 NO 2001004928 A 20011213 NO 2001-4928 20011010
 PRIORITY APPLN. INFO.: IT 1999-MI752 A 19990413
 WO 2000-EP3239 W 20000411

OTHER SOURCE(S): MARPAT 133:309791

AB Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.


IT 53910-25-1, Pentostatin

RL: RCT (Reactant); RACT (Reactant or reagent)
 (antitumor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 51481-61-9, Cimetidine

RL: RCT (Reactant); RACT (Reactant or reagent)
 (antiulcer; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:742053 CAPLUS
 DOCUMENT NUMBER: 133:310142
 TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
 INVENTOR(S): Del Soldato, Piero
 PATENT ASSIGNEE(S): Nicox S.A., Fr.
 SOURCE: PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
WO 2000061537	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1311924	B1	20020320	IT 1999-MI753	19990413
BR 2000009702	A	20020108	BR 2000-9702	20000411
EP 1169294	A2	20020109	EP 2000-925203	20000411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541233	T2	20021203	JP 2000-610814	20000411
NO 2001004927	A	20011213	NO 2001-4927	20011010
PRIORITY APPLN. INFO.:			IT 1999-MI753	A 19990413
			WO 2000-EP3234	W 20000411


OTHER SOURCE(S): MARPAT 133:310142
 AB Compds. A-B-C-N(O)s and A-C1[N(O)s]-B1 or their salts [s is an integer 1 or 2, preferably s = 2; A is the radical of a drug and is such as to meet the pharmacol. tests reported in the description; C and C1 are two bivalent radicals; the precursors of the radicals B and B1 are such as to meet the pharmacol. test reported in the description] were prepared for use as pharmaceuticals. Thus, (S,S)-N-acetyl-S-(6-methoxy- α -methyl-2-naphthalenylacetyl)cysteine 4-nitroxybutyl ester was prepared (NCX 2101) from naproxene and N-acetylcysteine in the first of 28 synthetic examples given. Pharmacol. test examples and tabular data are also given.
 IT 51481-61-9, Cimetidine 53910-25-1, Pentostatin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (drug precursor)
 RN 51481-61-9 CAPLUS
 CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:314524 CAPLUS

DOCUMENT NUMBER: 132:326077

TITLE: Oral administration of adenosine analogs

INVENTOR(S): Wrenn, Simeon M., Jr.

PATENT ASSIGNEE(S): Supergen, Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025758	A1	20000511	WO 1999-US25676	19991101
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6174873	B1	20010116	US 1998-185909	19981104
EP 1126828	A1	20010829	EP 1999-960184	19991101
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

JP 2002528487 T2 20020903
PRIORITY APPLN. INFO.:

JP 2000-579200 19991101
US 1998-185909 A 19981104
WO 1999-US25676 W 19991101

AB Disclosed are compns. including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compns. including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compns. including adenosine analogs, wherein the composition is in a dosage form comprising a liquid Pentostatin mixed with sterile water and Na saccharin was charged into a cup for oral administration.

IT 4291-63-8, Cladribine 51481-61-9, Cimetidine


53910-25-1, Pentostatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral administration of adenosine analogs)

RN 4291-63-8 CAPLUS


CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51481-61-9 CAPLUS


CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:200269 CAPLUS

DOCUMENT NUMBER: 120:200269

TITLE: Physical compatibility of melphalan with selected drugs during simulated Y-site administration

AUTHOR(S): Trissel, Lawrence A.; Martinez, Juan F.

CORPORATE SOURCE: M. D. Anderson Cancer Cent., Univ. Texas, Houston, TX, 77030., USA

SOURCE: American Journal of Hospital Pharmacy (1993), 50(11), 2359-63

CODEN: AJHPA9; ISSN: 0002-9289

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The phys. compatibility of melphalan injection with selected drugs during simulated Y-site administration was studied. None of the drug combinations resulted in visual evidence of precipitation, color change, or gas production. Most combinations had a measured turbidity of <0.1 nephelometric turbidity unit (NTU) and were compatible. A few combinations had turbidities of ≥0.1 NTU, but the turbidity did not change over the study period and the combinations were considered compatible.

Combinations of melphalan with methylprednisolone sodium succinate, prochlorperazine edisylate, or daunorubicin hydrochloride had a very small increase in turbidity but were compatible. Melphalan did not increase the doubling of turbidity that idarubicin hydrochloride shows upon simple dilution. Neither the total particle burden nor the number of particles of ≥10 µm increased in any combination that was tested. However, combinations with amphotericin B or chlorpromazine hydrochloride showed large increases in measured turbidity and were incompatible. Melphalan 0.1 mg/mL in 0.9% sodium chloride injection was phys. compatible with most of the drugs tested for up to three hours at 22°. Exceptions were combinations with amphotericin B and with chlorpromazine hydrochloride.

IT 53910-25-1, Pentostatin 70059-30-2, Cimetidine hydrochloride


RL: BIOL (Biological study)

(melphalan injection compatibility with, during Y-site administration)

RN 53910-25-1 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70059-30-2 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:116847 CAPLUS

DOCUMENT NUMBER: 120:116847

TITLE: Biodegradable controlled release melt-spun delivery system

INVENTOR(S): Fuisz, Richard C.

PATENT ASSIGNEE(S): Fuisz Technologies, Ltd., USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9324154	A1	19931209	WO 1993-US5307	19930602
W: AU, CA, HU, JP, KR, PL, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5518730	A	19960521	US 1992-893238	19920603
AU 9344058	A1	19931230	AU 1993-44058	19930602
AU 665844	B2	19960118		
JP 07507548	T2	19950824	JP 1994-500877	19930602
EP 746342	A1	19961211	EP 1993-914373	19930602
EP 746342	B1	20020814		
R: BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, SE				

PRIORITY APPLN. INFO.:

US 1992-893238 A2 19920603

WO 1993-US5307 A 19930602

AB Biodegradable controlled-release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dose forms as well as implants are described. For example, polyglycolide was melt-spun in combination with various drugs such as vancomycin, gentamicin, tolmetin, diphenhydramine, ibuprofen, and insulin and controlled drug release was demonstrated.


IT 53910-25-1, Pentostatin 70059-30-2, Cimetidine hydrochloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release pharmaceuticals formed by flash-flow melt-spinning containing, biodegradable polymers as carriers in)

RN 53910-25-1 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70059-30-2 CAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d his l11-

(FILE 'CAPLUS' ENTERED AT 11:54:42 ON 25 MAR 2003)

FILE 'STNGUIDE' ENTERED AT 12:00:09 ON 25 MAR 2003

FILE 'CAPLUS' ENTERED AT 12:09:20 ON 25 MAR 2003

L11 5 (L2 OR L4) AND CARBONATE
L12 3 L11 NOT L10

=> d 112 total ibib abs hitstr

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:136991 CAPLUS
DOCUMENT NUMBER: 134:198075
TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): Lipocene, Inc., USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309663	B1	20011030	US 1999-375636	19990817
EP 1210063	A1	20020605	EP 2000-947184	20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506476	T2	20030218	JP 2001-516502	20000710
US 2001024658	A1	20010927	US 2000-751968	20001229
US 6458383	B2	20021001		
PRIORITY APPLN. INFO.:			US 1999-375636 A	19990817
			WO 2000-US18807 W	20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18,

and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.


IT 4291-63-8, Cladribine 53910-25-1, Pentostatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination
of surfactants)

RN 4291-63-8 CAPLUS

CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53910-25-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-
pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1965:74477 CAPLUS

DOCUMENT NUMBER: 62:74477

ORIGINAL REFERENCE NO.: 62:13220c-e

TITLE: Nucleosides and nucleotides. XXIV. Purine
cyclonucleosides. 1. 8,2'-Cyclonucleoside derived from
2-chloro-8-mercaptop-9-β-D-xylofuranosyladenine

AUTHOR(S): Ikehara, Morio; Tada, Hiroshi

CORPORATE SOURCE: Hokkaido Univ., Sapporo, Japan


SOURCE: J. Am. Chem. Soc. (1965), 87(3), 606-10

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 60, 15966e. The synthesis of 2-chloro-8-mercaptop-9-(2-O-acetyl-3-O-p-tolylsulfonyl-O-methoxycarbonyl- β -D-xylosyl)adenine (I) was achieved by Davoll's method. I gave 8,2'-anhydro-2-chloro-8-mercaptop- β -D-arabino-furanosyladenine (II) on treatment with NaOMe in MeOH. The structure of II was elucidated by chem. and phys. methods. Desulfurization of II with Raney Ni followed by hydrogenation over Pd-C gave 2'-deoxyadenosine, identical with naturally occurring nucleoside. Hydrolysis of II in acidic and alkaline media was investigated.
 IT 4291-63-8, Adenosine, 2-chloro-2'-deoxy-
 (preparation of)
 RN 4291-63-8 CAPLUS
 CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1964:418521 CAPLUS
 DOCUMENT NUMBER: 61:18521
 ORIGINAL REFERENCE NO.: 61:3186d-e
 TITLE: New type of cyclonucleoside derived from 2-chloro-8-mercaptop-9- β -D-xylofuranosyladenine
 AUTHOR(S): Ikehara, Morio; Tada, Hiroshi
 CORPORATE SOURCE: Hokkaido Univ., Sapporo, Japan
 SOURCE: J. Am. Chem. Soc. (1963), 85(15), 2344-5
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB 2-O-Acetyl-5-O-methoxycarbonyl-3'-O-tosyl-D-xylofuranosyl chloride with 2,8-dichloroadenine mercuri-chloride in boiling xylene gave 9-(2'-O-acetyl-3'-O-tosyl-5'-O-methoxycarbonyl)-2,8-dichloro- β -D-xylofuranosyladenine (I). I with CS(NH2)2 gave the 8-mercaptop derivative (II). II with NaOMe in boiling MeOH gave 8,2'-anhydro-2-chloro-8-mercaptop-D-xylofuranosyladenine (III). III with Raney Ni gave 2-chloro-2'-deoxyadenine (IV). Hydrogenation of IV gave 2'-deoxy-adenosine.
 IT 4291-63-8, Adenosine, 2-chloro-2'-deoxy-
 (preparation of)
 RN 4291-63-8 CAPLUS
 CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

